University of New Mexico

UNM Digital Repository
Health, Exercise, and Sports Sciences ETDs

Education ETDs

9-9-2010

Are thermotolerance and heat acclimation related
through the heat shock response?
Matthew Kuennen

Follow this and additional works at: https://digitalrepository.unm.edu/educ_hess_etds
Recommended Citation
Kuennen, Matthew. "Are thermotolerance and heat acclimation related through the heat shock response?." (2010).
https://digitalrepository.unm.edu/educ_hess_etds/22

This Dissertation is brought to you for free and open access by the Education ETDs at UNM Digital Repository. It has been accepted for inclusion in
Health, Exercise, and Sports Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.

ARE THERMOTOLERANCE AND HEAT ACCLIMATION RELATED
THROUGH THE HEAT SHOCK RESPONSE?

BY

MATTHEW R. KUENNEN
B.A., Health Promotion, University of Northern Iowa, 2003
M.A., Exercise Physiology, University of Northern Iowa, 2005

DISSERTATION
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Physical Education, Sports and Exercise Science
The University of New Mexico
Albuquerque, New Mexico
July, 2010
i

ARE THERMOTOLERANCE AND HEAT ACCLIMATION
RELATED THROUGH THE HEAT SHOCK RESPONSE?

BY

MATTHEW R. KUENNEN

ABSTRACT OF DISSERTATION

Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Physical Education, Sports and Exercise Science
The University of New Mexico
Albuquerque, New Mexico
July, 2010

ii

Are Thermotolerance and Heat Acclimation Related Through the Heat Shock
Response?
by
Matthew R. Kuennen
B.A., Health Promotion, University of Northern Iowa, 2003
M.A., Exercise Physiology, University of Northern Iowa, 2005
PhD Physical Education, Sports & Exercise Science, University of New Mexico, 2010

ABSTRACT

Thermotolerance (cellular adaptations that allow survival after an acute, severe
heat exposure) and heat acclimation (systemic adaptations that improve heat dissipation
following chronic heat exposure) have traditionally been considered separate phenomena.
However, recent studies in animals suggest these adaptations may be related through the
heat shock response. METHODS: We evaluated the effects of a standard laboratory heat
shock response-inhibitor (QUERCETIN) on established markers of thermotolerance
[gastrointestinal barrier permeability, plasma TNF-a, Il-6, and Il-10 concentrations;
leukocyte HSP70 content(HSP70)] and heat acclimation [reduced body temperatures,
heart rate, and physiologic strain in response to exercise/heat stress] in male subjects
(n=8) completing a 7-day heat acclimation protocol. Thermotolerance markers were
assessed in blood drawn before (pre), after (post), 2hr after (2-post) and 4hr after (4-post)
exercise on day 1 and day 7 of heat acclimation. Heat acclimation markers were assessed by
a standard heat tolerance test, performed at baseline, and on day 6 of heat acclimation.

Subjects completed an identical protocol under placebo supplementation (PLACEBO), in
iii

counter-balanced order, under double-blind conditions, with sufficient washout.
RESULTS: QUERCETIN increased gastrointestinal barrier permeability and TNF-a on
the 1st day of exercise/heat stress, no differences in these variables were reported in
PLACEBO. 7 days of exercise/heat stress in PLACEBO decreased subjects’ exercise Il-6
and Il-10 and increased HSP70; it also reduced exercise body temperatures, heart rate,
and physiologic strain. Striking differences were noted in these same subjects under
QUERCETIN. Here gastrointestinal barrier permeability remained elevated, Il-6 and Il10 were not reduced, HSP70 was not increased, and exercise body temperatures were not
reduced. While exercise heart rate and physiologic strain were reduced, this occurred
much later in exercise. CONCLUSIONS: Consistent with the concept of wholeorganism adaptation, repeated exercise/heat stress reduces circulating cytokine
concentrations and increases cytoprotective HSP70, contributing to reductions in
systemic markers of heat strain. Exercising under the influence of a heat shock response
inhibitor may prevent these responses, contributing to loss of benefits normally incurred
by a standard heat acclimation protocol in humans.
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CHAPTER 1
Introduction
The pathophysiology of exertional heatstroke is not well understood. Current
research suggests that increased intestinal cell permeability may predispose humans to
this potentially fatal illness (Bouchama et al. 2002; Lim et al. 2006). Performance of
physical work in hot ambient conditions increases blood flow to active skeletal muscle
and skin (Rowell, 1974). The additional blood flow is obtained by shunting blood from
the splanchnic tissues. While not a problem at moderate exercise intensities, the
combination of severe exercise and heat stress have been shown to reduce splanchnic
perfusion by >70%, potentially causing ischemia in intestinal barrier cells (Rowell et al.
1965). Reduced splachnic blood flow reduces heat loss by convection to the circulating
blood and leaves splanchnic tissues with inadequate oxygen supply (Lambert, 2008). The
resultant rise in splanchnic tissue temperature and oxygen radical generation damages
lipid membranes and fragments DNA (Finaud, 2006), reducing the structural integrity of
the intestinal barrier (Ding et al. 2004; Kriegel et al. 1988; Lambert et al. 2002).
The gastrointestinal tract is the major source of endogenous endotoxin, and
epithelial cell damage allows endotoxin entry into the portal circulation (Baker et al.
1988). Fixed tissue macrophages in the liver (Kupfer cells) respond to circulating
endotoxin by secreting pro-inflammatory cytokines (TNF-a, Il-6) that target endotoxin
removal (Jaeschke, 1997). Cytokine release by Kupfer cells activates circulating
leukocytes and has a profound impact on surrounding tissues (Nathan, 1987). These
cytokines increase concentrations of adhesion molecules on the surface of leukocytes and
endothelial cells, facilitating reduced leukocyte rolling rates, firm adhesion, and
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subsequent leukocyte migration into the interstitum (Sumagin & Sarelius, 2006). These
processes are important in the pathogenesis of microvascular injury. Neutrophils are the
first responders to bacterial infection. Following activation by circulating inflammatory
cytokines (Il-1b, Il-6, TNF-a) (Robertson et al. 1996), neutrophils produce microbicidal
agents that allow them to phagocotize LPS. Increased release of these agents is
problematic, causing damage to epithelial and endothelial barriers in small intestine and
liver tissues, and perpetuating the inflammatory response (Bannerman et al. 2003).
Barrier damage facilitates increased LPS extravasation from the gut, over-whelms
the protective mechanisms of the portal circulation and immunoregulatory mediators in
the liver, and results in a release of LPS into the systemic circulation. Plasma LPS
concentrations as low as 4 ng/kg have been shown to induce a pyretic and hypotensive
response in otherwise healthy humans (Suffredini et al. 1989). Greater LPS titers have
been implicated in sustained inflammatory responses (Bouchama et al.1991),
disseminated intravascular coagulation (al-Mashhadani et al. 1994), adult respiratory
distress syndrome (Streiter et al. 1990), and diffuse liver injury (Deaciuc et al. 1999). All
four morbidities are associated with severe heatstroke (Moseley & Gisolfi, 1993), which
culminates in multiple organ failure and death (Lumlertgul et al. 1992).
Conversely, exposure to lesser thermal and oxidative stressors produces a state of
cell thermotolerance. Much of this effect can be attributed to activation of the heat shock
response, more specifically to increased heat shock protein (HSP) synthesis. Briefly, HSP
function as molecular chaperones, ensuring newly synthesized proteins achieve their
proper configuration and cellular locale (Moseley, 1997). In unstressed and/or quiescent
cells, HSP localize to the cytosol. Here they bind the heat shock factor 1 (HSF-1),
2

transcript, retaining HSF-1 in its native inactive conformation. Stress exposure results in
translational arrest, causing aggregation of protein fragments within the cell (Hildebrandt
et al. 2002). Protein accumulation competes HSP from HSF-1,binding HSP and leaving
HSF-1 free to trimerize and enter the nucleus. Binding of HSF-1 to promoter elements on
DNA stimulates new HSP synthesis (Wu, 1995).
HSP family members range from 27 to 110 kDa, and expression varies by cellular
locale and tissue type (Moseley, 1997). The 72-kDa protein (HSP72) has been examined
extensively, and has been shown to be highly inducible by both thermal and oxidative
stressors (Sonna et al. 2002; Horowitz et al. 2004). Exposing rats (Flanagan et al. 1995;
Kokura et al. 2007), rabbits (Manzerra et al. 1997) and pigs (Sepponen et al. 2006) to
these stressors increases HSP72 expression in small bowel, colon, and liver tissues.
HSP72 upregulation in these tissues reduces inflammation, morbidity, and mortality from
LPS challenge (Dong et al. 2005; Hung et al. 2005; Kluger et al. 1997). It also improves
survival in ischemic (Juel et al. 2008; Stojadinovic et al. 1995) and thermal (Weshler et
al. 1984) heat stroke simulations. In contrast, animals that have been pharmacologically
or genetically manipulated to suppress HSP72 induction receive little or no benefit from
prior stress exposure (Dokladny et al. 2001; Huang et al. 2001). Their response is similar
to or worse than control animals upon subsequent challenge.
Tissue culture studies suggest a potential mechanism for the improved stress
tolerance seen in these animals. Here human epithelial cells are cultured to produce
monolayers, which are an accepted in-vitro simulation of intact epithelium. It was first
shown that exposing cultured Madin-Darby Canine Kidney Cell (MDCK) monolayers to
preconditioning heat stress (42ºC for 90 minutes) increases the temperature required for
3

barrier disruption, as measured by an increase in mannitol permeability (Moseley, 1994).
This benefit was later tied to paracellular barrier improvements, including showing
greater integrity of tight junctions between adjacent cells and reductions in paracellular
transport of large molecules in the period following preconditioning stress exposure
(Dokladny, 2006a; 2006b). This benefit was blocked by suppressing the heat shock
response with quercetin during the preconditioning heat exposure. More recently
occludin, a tetra-span protein vital to paracellular barrier function in the gastrointestinal
epithelium was also shown to be up-regulated by a physiologically relevant heat stress
(39ºC) (Dokladny, 2008). Taken together, these studies indicate that a physiologically
relevant hyperthermia (between 39 and 42ºC) increases HSP72 and occludin expression
in simulated intestinal epithelium, the combination of which cause paracellular barrier
improvements.
Commonalities between these cell culture experiments and exercise/heat stress in
human subjects suggest a similar mechanism. First, intestinal barrier disruption is often
noted in humans following acute bouts of exercise in desert heat (Camus et al. 1997;
Jeukendrup et al. 2000; Ng et al. 2008; Pals et al. 1997). Second, repeating this
exercise/heat stress in animal or human subjects over multiple days causes significant
increases in HSP72 expression (Amorim et al. 2008; Horowitz et al. 2004; McClung et al.
2008; Yamada et al. 2007). Third, as compared to a control population, heat intolerant
subjects exhibit lower HSP72 titers both inside and outside of the cell in response to
thermal stimuli (Moran et al. 2006; Wang et al. 2001; Wu et al. 2001). Finally, following
severe exercise/heat stress trained subjects report lower circulating LPS concentrations
than their untrained counterparts (Selkirk et al. 2008). Collectively, these studies suggest
4

that increased tolerance afforded to human subjects by repeat exercise/heat stress may
result from intestinal cell barrier improvements and reductions in LPS extravasation into
circulation. Like the cell culture and animal models discussed previously, HSP72
overexpression is vital to this response.
Application to US military personnel:
Carrying heavy rucksacks and hot environmental exposure cause military soldiers
significant oxidative stress (Bachkosky et al. 2007). This stress has been implicated in
skeletal muscle microtrauma, sustained inflammation, and non-specific
immunosupression (Brown et al. 2007; Malm, 2006; Murphy et al. 2008; Nieman et al.
1990; Powers et al. 2008). Quercetin (3,3’4’,5,7-pentahydroxyflavone) is a dietary
flavanol that affords powerful antioxidant (Boots et al. 2008), anti-inflammatory (Nair et
al. 2006), and antiviral (Davis et al. 2008; Nieman et al. 2007) effects in-vitro and invivo. In early 2009 military oversight committees adapted quercetin into energy bars as a
nutraceutical countermeasure to aid soldiers during high stress military deployments
(Natick, 2009).
Although used here to improve soldier health, it would surprise many that
quercetin was originally examined for its cytotoxic effects. A 1990 article in “Cell
Structure and Function” provides a good summation. It states:
“A number of biological effects of quercetin have been reported; the inhibition of
cultured cell growth, inhibitory effects on glycolysis, macromolecule synthesis, activity
of protein kinases, and ATPases… Quercetin is reported to be a hyperthermic sensitizer
in HeLa cells.” (Hosokowa et al. 1990).
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This statement is troubling, particularly the mention of hyperthermic sensitization.
This sensitivity is the result of suppressed protein kinase signaling, which also
contributes to reduced HSP synthesis in response to physiologic stressors (End et al.
1987). Cell and tissue culture experiments indicate quercetin reduces HSF-1
phosphorylation, trimerization, and nuclear entry, preventing HSP72 expression and
restitution of paracellular barrier integrity following physiologic stress (Dokladny et al.
2006a; 2006b; 2008). The results of these tissue culture experiments have also been
extended to animal models. Pharmacological increases in liver HSP72 expression have
been reported to protect rats against LPS-induced liver damage, pro-inflammatory
cytokine production (TNF-a and Il-6), and LPS-induced mortality (Nakada et al. 2005).
However, combining oral quercetin supplementation with pharmacological HSP72
stimulators prevented the increase in liver HSP72 and left rats no more protected then
controls (Nakada et al. 2005). Pharmacological HSP72 overexpression has also been
adapted to an intestinal wounding model. Here HSP72 over-expressing rats were better
able to restitute the gastric barrier following wounding, resulting in reduced infiltration of
inflammatory cells. In contrast, when oral quercetin supplementation was combined with
the stimulus for HSP72 overexpression, HSP72 was not increased. This prevented rats
from restituting the intestinal barrier, and fared worse than control animals (Liu et al.
2007).
While differences in dosing and bioavailability prevent direct extrapolation of
these animal results to a human model, emerging evidence suggests the effects may be
similar. First, humans metabolize quercetin in the hepatosplanchnic tissues (Rechner et
al. 2002). Using a porcine model to simulate human gastrointestinal physiology, Biegler
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et al. (2008) showed a single oral quercetin dose (25 mg/kg) significantly increased
quercetin concentrations in liver, jejunum, and colon tissues. Second, bioavailability of
ingested quercetin is moderate to high in human subjects (Hollman et al. 1995). Third,
hepatosplanchnic tissues benefit most from the heat shock response following
exercise/heat stress (Dong et al. 2005; Flanagan et al. 1995; Hung et al. 2005; Kluger et
al. 1997; Kokura et al. 2007; Manzerra et al. 1997; Juel et al. 2008; Sepponen et al. 2006;
Stojadinovic et al. 1995; Weshler et al. 1984). Taken together, these studies suggest
quercetin may be sequestered in hepatosplancnic tissues in concentrations sufficient to
diminish the preconditioning response. This may be a significant concern for military
soldiers exposed to exercise/heat stress, as it may increase susceptibility to heat illness.

Problem Statement
Oral quercetin supplementation is being supplied to military soldiers experiencing
oxidative stress, but the possibility of a suppressed heat shock response and increased
susceptibility to heat illness have not been examined.

Purpose of Study
This study examined the effect of 1000 mg twice-daily quercetin supplementation
on physiological adjustments to a 7 day heat acclimation (HA) protocol. Researchers
hypothesized that while subjects in the quercetin supplemented condition would appear
heat acclimated according to traditional measures (improved sweat rate, heart rate, and
body temperature responses to exercise stress), the suppressed heat shock response would
limit their protection against heat illness. To test this hypothesis subjects underwent HA
7

in both quercetin and placebo supplemented conditions. Intestinal permeability was
measured with lactulose sugar probes in each condition, at baseline, and on the 1st and
7th days of HA. This allowed assessment of both transient and sustained quercetin dosing
effects on intestinal permeability. Plasma quercetin was measured to verify that the
quercetin was absorbed and increased in the circulation in the quercetin supplemented
condition.
Quercetin is a potent antioxidant/anti-inflammatory agent (Boots et al. 2007).
Endotoxin activation of inflammatory cytokines is a major cause of organ and tissue
injury in heat illness. Thus, there is no guarantee a significant leak detected by lactulose
sugar probes is physiologically relevant, as the beneficial effects of quercetin may buffer
its’ detrimental effects of endotoxin leakage. The inflammatory cytokines TNF-a and Il6, and the anti-inflammatory cytokine Il-10 were assessed in plasma to examine the net
inflammatory response. Because an insufficient cellular heat shock response is thought to
drive the detrimental effects of quercetin, HSP72 was assessed in peripheral blood
mononuclear cells (PBMC) with the assumption that changes in leukocytes are
representative of changes in other heat-sensitive cells of the body.

Hypotheses
The following research hypotheses were tested in this study.
Hypothesis I. 2g daily quercetin supplementation will reduce thermotolerance at the level
of the gastro-intestinal tissues, resulting in increased (p < .05) urinary lactulose excretion
and endotoxin levels in plasma on days 1 and 7 of exercise/ heat stress.
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Rationale. Suppression of the preconditioning response has been shown in isolated cells,
tissues, and intact animals (Hosokowa et al. 1990; Dokladny et al. 2006; Nakada et al.
2005). Quercetin appears in high concentration in splanchnic tissues (Biegler et al. 1998).
Quercetin mediated suppression of paracellular barrier conditioning following
exercise/heat stress would allow lactulose and endotoxin increased access to circulation.
Hypothesis II. 2g daily quercetin supplementation will attenuate (p < .05) the expected
increase in HSP72 content of peripheral blood mononuclear cells responding to 7 days of
exercise/heat stress.
Rationale. Reduced activity of HSF-1 and associated gene products have been shown in
tissue culture and animal models. While these effects have not been attributed to
quercetin in a human model, suppressed leukocyte expression of HSF-1 and HSP72
following exhaustive treadmill exercise was shown in humans supplemented with αtocopherol, a similar antioxidant (Fischer et al. 2006; Niess et al. 2002). Suppression of
HSP72 is one mechanism thought to contribute to reduced epithelial barrier integrity in
cultured monolayers exposed to heat stress under quercetin supplementation (Dokladny et
al. 2006).
Hypothesis III. The increase (p < .05) in epithelial barrier permeability in subjects
exercising under 2g/d quercetin supplementation will be accompanied by concomitant
increases (p < .05) in inflammatory (TNF-a and Il-6) and anti-inflammatory (Il-10)
cytokine levels in plasma.
Rationale. Quercetin mediated suppression of paracellular barrier conditioning following
exercise/heat stress would allow endotoxin increased access to circulation. Endotoxin
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stimulates an exaggerated immune response, characterized by increased inflammatory
and anti-inflammatory cytokine concentrations in plasma (Bannerman et al. 2003).
Hypothesis IV. 2g daily quercetin supplementation will diminish subject’s capacity to
acclimate to 7 days of exercise/heat stress, resulting in reduced (p < .05) improvements in
systemic markers of heat acclimation (core, mean skin, mean body temperatures; heart
rate; physiological strain).
Rationale. While there is no published evidence that quercetin’s mechanism of action
interferes with these adaptations, animal models of proponolol-mediated HSP72
suppression (Maloyan et al. 2002) and studies on thermotolerance and impaired HSP72
response (Moran et al. 2006) suggest this may occur.

Scope of the Study
Eight healthy male subjects repeated two 7-day heat acclimation conditions.
Subjects took quercetin in one condition, and placebo (powdered food coloring of similar
color and texture) in the other. At least 3 months elapsed before subjects were allowed to
repeat the study in the opposite condition. The order was balanced, quercetin
supplementation was double blind, and the study was performed in winter months to
minimize potential for natural heat acclimitization. Subjects were instructed to avoid
caffeine, alcohol, anti-oxidant vitamins, and to stay well hydrated. They were also
instructed to avoid exercise and heat exposure that was not directly outlined by the
experiment. During the study period subjects ate packaged meals prepared by licensed
dieticians to ensure adequate nutrition and to avoid high dietary quercetin intake.
Average dietary quercetin intake by Westerners is 20 mg/d, and the upper limit in these
10

meals was set at 10mg/d. As subjects were provided with 2g quercetin per day in the
supplemented condition, this represents a 200 fold increase over possible dietary
inclusion.
Each condition began with a basal measurement of intestinal permeability, at rest,
in non-exercise/heat stress conditions. This provided a control value for intestinal
permeability for each subject, to which subsequent exercise/heat stress values were
compared. This was followed by an acute thermal challenge, used as a baseline
measurement of subject’s capacity to work in the heat. After a 1-week washout to avoid
carryover, each subject completed 7 days of exercise in a hot room (100 min/day).
Subjects performed additional measures of intestinal permeability on days 1 and 7 of heat
acclimation, allowing researchers to examine the effects of acute and chronic heat
exposure on gastrointestinal barrier function, under normal conditions, and also under the
influence of quercetin. The absolute exercise workload and ambient environmental
conditions on day 6 of heat acclimation were identical to that of the acute thermal
challenge, providing a posttest measure of each subjects’ capacity to work in the heat
(indicating acquisition of heat acclimated phenotype).

Assumptions
The following assumptions were made in this study.
1. Subjects did not perform external exercise during the data collection period.
2. Subjects consumed all foodstuffs provided by study dieticians, both inside and
outside of the hospital
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3. Subjects avoided consumption of outside foodstuffs, and were truthful in their
responses on the dietary recall.
4. Subjects properly mixed all quercetin or placebo supplemented drinks, consumed
all drinks in combination with their last daily meal, and avoided external dietary
supplementation with quercetin or antioxidant vitamins.
5. The three month washout period between heat acclimations was sufficient to
avoid any carryover effects. College-aged male subjects were an accurate
representation of military soldiers and endurance athlete populations.
6. A laboratory exercise/heat stress test is representative of field conditions.
7. Differences in systemic markers of heat acclimated phenotype and cellular
markers of acquired thermotolerance between quercetin and placebo
supplemented conditions can be attributed to inhibition of the heat shock
response, and not other properties inherent to quercetin, the subject, the heat, or
the exercise.
8. While urinary lactulose excretion was measured under non-exercise/heat stress
conditions (control), and then following acute and chronic exercise/heat stress, it
is possible external influences (gastrointestinal transit, subject adherence to
experimental protocol) may have influenced subject responses. We assume
delimiting the subject population to Exercise Science graduate students, and
further confining said subjects to the UNM General Clinical Research Center the
night prior to each trial, minimized the likelihood this occurred.
9. HSP72 is an acceptable representation of other cells, including circulating
leukocytes, fixed macrophages, and epithelial/endothelial cell barriers.
12

10. Increased concentrations of the plasma cytokines measured in this study (TNF-a,
Il-6, Il-10) are largely influenced by gastrointestinal barrier leak, and not unduly
influenced by exercise alone, heat stress alone, or subject-specific differences.
11. The plasma cytokines measured in this study accurately reflect the desired study
outcomes. Meaning other cytokines, or other mediators altogether, would not
have provided a more meaningful outcome.

Limitations
The following limitations were identified for this study.
1. The study group consisted of healthy males in the age range of 18 to 40 years old;
therefore, study results can only be generalized to a healthy population of similar
age and the same gender.
2. A single dose (2g) of daily quercetin supplementation was used in this study,
leaving the possibility that non-significant findings may be related to dosing
issues.
3. To ensure adequate experimental control, environmental temperatures, subject
medical history, subject stress-exposure history, subject diet, subject hydration
status, and subject external activities (exercise, heat, and UV exposure) were
carefully reviewed/controlled prior to study onset, and during study participation.
This level of experimental control is not representative of true conditions for
either the military or endurance athlete populations of interest.
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Significance of Study
This study identified whether quercetin’s capacity to suppress the heat shock
response resulted in increased gastrointestinal permeability when provided to subjects
during repeat days of exercise in the heat. This study is unique, as both significant
and non-significant findings would benefit the scientific community. Quercetin’s
thermo-sensitizing capacity in cell culture has never been analyzed in animals, much
less humans. If quercetin were to cause significant gastrointestinal permeability and
increase bacterial translocation, this information should be considered by the military
oversight committees. We hope this would lead to re-examination of the proposed
utility and safety of this supplement for soldiers experiencing heat stress. Nonsignificant findings would indicate that the highest dose fielded to-date does not put
soldiers at increased risk of heat illness.
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Definition of Terms
The terms in this study have been operationally defined as follows:
Bioavailability. Metabolic availability of an ingested substance.
Exertional heat stroke. Life threatening event characterized by core temperature >40ºC,
sustained inflammatory response, disseminated intravascular coagulation, adult
respiratory distress syndrome, and diffuse liver injury.
Flavanol. Subgroup of larger flavonoid family that uses the 3-hydroxyflavone backbone.
Gram negative bacteria. Pathogenic bacterial strain that stains negative for granules
(synonymous with endotoxin). LPS is a cell wall constituent of gram negative bacteria.
Heat intolerance. Inability to tolerate physical activity in hot ambient conditions,
evidenced by increased susceptibility to heat stroke.
Hepatosplanchnic tissues. Combination term for small intestine, large intestine, and liver
tissues.
Occludin. 62 kDa tetra-span protein isoform vital to paracellular barrier integrity.
Reactive oxygen species. Molecule that contains an unpaired electron in outer orbital.
Reactive oxygen species contribute to pathophysiology of exertional heat stroke.
Trimerization. An activated transcription factor co-localizes with two like factors,
forming a trimer complex.
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CHAPTER II
REVIEW MANUSCRIPT
This chapter presents a review manuscript, entitled “Heat shock proteins and heat
adaptation of the whole organism: An update” that will be submitted to the Journal of
Applied Physiology. It is authored by Matthew Kuennen, Trevor Gillum, Karol
Dokladny, Sue Schneider, and Pope Moseley. The manuscript follows the formatting and
style guidelines of the journal. The references cited are provided at the end of the
manuscript.
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Abstract:
Thermotolerance and acclimatization are two key adaptations to heat exposure that have
traditionally been regarded as separate phenomena. In 1997 we proposed that these
responses were integrated, and reviewed contributions of the heat shock response to heat
adaptation of the whole organism. Research over the past 13 years has provided
considerable evidence supporting this claim, in animals and humans, in both laboratory
and natural settings. Insufficient activation of the heat shock response may also
contribute to heat intolerance in animal and human populations; this concept is supported
by recent laboratory studies reporting blockade of both thermotolerance and acclimation
in animals and humans that were exposed to heat and exercise/heat stress under the
influence of pharmacologic inhibitors of the heat shock response . While the mechanism
behind this loss of acclimatory fitness is not well understood, current research suggests an
insufficient heat shock response may contribute to greater exercise/heat stress induced
disruptions of the gastrointestinal barrier, resulting in systemic inflammation and
perturbed thermoregulatory responses. This evidence is reviewed.
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Introduction:
Paragraph 1 In 1997 we reviewed contributions of the cellular stress response (called
thermotolerance) to heat adaptation of the whole organism (called acclimatization).
Despite the limited data available at that time, we speculated that “heat acclimatization is
the result of the organism’s ability to dissipate heat more effectively as well as the
organism’s ability to either block or tolerate gut-associated endotoxin translocation,
downregulate cytokine production, or develop an increased tolerance to cytokine
exposure” (66). In 2002 a colleague introduced the concept of “cross tolerance”,
providing evidence that the increase in heat shock protein expression following stress
exposure, in conjunction with the ensuing cellular responses, confers tolerance for a
variety of stressors at the level of the integrated organism. He concluded this review with
the comment “Despite the significant amount of progress that has been made regarding
biochemical and structural features of HSP70, the mechanisms by which these proteins
provide protection against cellular stress are still not thoroughly understood.” (45).

Paragraph 2 Now, in 2010, the number of studies addressing thermotolerance and heat
adaptation at the level of the integrated organism have increased exponentially. Therefore
we now propose that our prior definition of thermotolerance as a “cellular adaptation
caused by a single, severe but nonlethal heat exposure that allows the organism to survive
a subsequent and otherwise lethal stress” is inherently flawed. To rectify this oversight,
we have coined a new term, “integrated thermotolerance” which we define here as “an
integrated series of adaptations in cells, tissues, and the whole organism, caused by one
severe or multiple moderate exposures to any stressor sufficient to activate the heat shock
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response, which allow the organism to tolerate exposure to lesser disruptive stressors
and survive an otherwise lethal stress.” In this paper we review evidence supporting
integrated thermotolerance contributing to heat adaptation of the whole organism, in
animals and humans, in laboratory and natural settings. Further, we provide evidence of
an impaired heat shock response contributing to heat intolerance of the whole organism,
in animals and humans, in laboratory and natural settings.

I. Tissue Responses to Thermal Challenge
Paragraph 3 Based on available literature, it is now clear that some of the symptoms
associated with exertional heat illness in humans can be traced back to stress-induced
disruptions of the gastrointestinal barrier (54). One major question has been the role of
the heat shock proteins in preventing this response. Due to complexities associated with
the integrated organism, it is sometimes cleaner to examine this question in tissue culture
experiments. The following sections review evidence supporting contributions of the heat
shock response to integrated thermotolerance in tissue culture experiments, as well as
evidence supporting suppression of the heat shock response as a means to prevent
integrated thermotolerance acquisition.

Evidence that the heat shock response confers integrated thermotolerance in confluent
monolayer tissue models.
Paragraph 4 Both severe and physiologically relevant temperature exposures have been
shown to compromise epithelial barrier integrity, and strong linear correlations have been
noted between the loss of barrier integrity and severity of thermal exposure (15, 65). In
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contrast, prior exposure to both modest (39°C) and severe (42°C) preconditioning heat
stress increases: 1) HSP70 protein expression (15, 16, 65); 2) junctional localization of
occludin, a tight junction protein (16, 17); and 3) the temperature required to elicit barrier
disruption (65). The on/off kinetics of gain and loss of improved barrier function
correlate linearly with HSP70 synthesis and decay (65). Genetically altering monolayers
to constitutively over-express HSP70 confers identical protection (16), underscoring the
contribution of this gene product to barrier integrity. Parallel findings have been reported
in isolated gastrointestinal cells (71) and liposome models (98).

Suppressing or removing the heat shock response prevents acquisition of integrated
thermotolerance in confluent monolayer tissue models.
Paragraph 5 Quercetin is a pharmacological HSF-1 inhibitor that has been reported to
sensitize laboratory animals (68) and cancer patients (21) to severe thermal and LPS
exposure. Adding quercetin to monolayer experiments: 1) increases the severity of heatinduced epithelial barrier disruption in unconditioned monolayers (15); 2) blunts the
increase in HSP70 protein expression following preconditioning heat stress (15, 16); 3)
reduces preconditioning-mediated increases in tight junction proteins (16, 17); and 4)
removes the benefit of preconditioning heat stress on epithelial barrier permeability (15,
16). These results have been replicated using the protein-synthesis inhibitor
cyclohexamide (16) and siRNA depletion of HSF-1 (17), supporting suppression of the
heat shock response as the mechanism by which this loss of function occurs.
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II. Whole Body Responses to Exertional Heat Stress
Overview of the heat shock response.
Paragraph 6 Do these results in monolayer experiments translate to humans
experiencing exertional heat stress? Based on available data, we can now confidently
state that exertional heat stress increases 1) large molecule permeability of the
gastrointestinal barrier (74); 2) endotoxin translocation into circulation (24, 81); and 3)
resulting inflammatory cytokine cascades (81, 82). The following paragraph contains an
abbreviated description of how these reactions are mediated.

Paragraph 7 Exercise in hot ambient conditions requires increased perfusion to both
exercising skeletal muscle and to the skin for thermoregulation. Blood is shunted away
from splanchnic tissues to meet the increased perfusion need. The reduction in splanchnic
perfusion has been reported to exceed 70% during severe exertional heat stress (78). The
splanchnic circulation is particularly susceptible to reduced blood flow. The combination
of hypoxic, ischemic, and thermal stressors reduces epithelial barrier integrity of
gastrointestinal tissues (12, 45, 46, 48). The gastrointestinal tract is the major source of
endogenous endotoxin, and epithelial cell damage allows endotoxin entry into the portal
circulation. Fixed tissue macrophages in the liver (Kupfer cells) respond to circulating
LPS by secreting pro-inflammatory cytokines (TNF-a, Il-6) that target LPS removal (39).
Cytokine release by Kupfer cells activates circulating leukocytes and has a profound
impact on surrounding tissues. These cytokines increase concentrations of adhesion
molecules on the surface of leukocytes and endothelial cells (91), facilitating leukocyte
rolling, firm adhesion (31), and subsequent migration into the interstitum. These
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processes are important in the pathogenesis of microvascular injury. Neutrophils are the
first responders to bacterial infection. Following activation by circulating inflammatory
cytokines (Il-1b, Il-6, TNF-a) (77), neutrophils produce microbicidal agents that allow
them to phagocotize LPS. Increased release of these agents is problematic, causing
damage to epithelial and endothelial barriers in small intestine and liver tissues, and
perpetuating the inflammatory response (2). Barrier damage facilitates increased LPS
extravasiation from the gut, which can overwhelm the protective confines of the portal
circulation and immunoregulatory mediators in the liver, resulting in LPS spillover into
the systemic circulation (1). Resulting systemic inflammation and hypercoagulation states
contribute to multiple organ dysfunction, and in severe cases, death (4, 56).

The heat shock response confers integrated thermotolerance in laboratory animal
experiments.
Paragraph 8 Based on the above model of exertional heat illness, heatstroke pathology
is caused by: 1)increased gastrointestinal barrier permeability; 2)extravasation of gut
bacteria into the portal circulation; 3) targeted immune responses against gut bacteria in
the liver, portal, and systemic circulations; and 4) cytokine-mediated chemotaxis of
immunoregulatory mediators. From these observations, methods targeting
epithelial/endothelial barrier integrity, gut bacteria, and cytokines should reduce
susceptibility to heat illness. Heat shock preconditioning has been shown to target these
weak links in the integrated organism. The following sections detail how these benefits
are conferred.
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Paragraph 9 Macrophages: Liver Kupfer cells represent 80-90% of fixed tissue
macrophages in the reticuloendothelial system (69). Preconditioning macrophages
at febrile-range temperatures (39.5°C) attenuates LPS stimulated TNF-a and Il-1b
expression (9, 19). Macrophages that constitutively over-express HSP70 exhibit
similar protection, in the absence of a preconditioning heat stress (13). LPSinduced NFKB activation, IKBA degradation, and resulting inflammatory
cytokine (TNF-a and Il-6) production are attenuated in RAW 264.7 macrophages
(84) and Kupfer cells of mice treated with sodium arsenite to induce HSP70
protein expression (92). HSF-1, the transcription factor that stimulates increased
HSP70 expression, also acts directly to suppress inflammatory cytokine
production by interacting directly with the TNF-a promoter region (85).

Paragraph 10 Liver: Preconditioning heat stress renders rats (42) resistant to
endotoxin-induced mortality. The time course of this protection is positively
correlated with the induction of HSP70 in the liver (22). Identical protection has
been shown in rats using exercise as the preconditioning stimulus and induced
heatstroke as the challenge variable (38). This protection is associated with 1)
attenuated hepatocyte apoptosis (41); 2) accelerated recovery of transcriptional
processes in hepatic tissues following LPS challenge (73); and 3) reductions in
liver and plasma TNF-a and Il-6 concentrations (14, 17, 38, 42). Invoking the heat
shock response via thermal preconditioning reduces LPS-induced NF-KB
activation and IKBA degradation (75, 76), in a manner identical to that described
for cultured macrophages above. Similar findings have been reported in mice
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infected with an adenovirus vector that causes over-expression of HSP70 in liver
tissues in the absence of preconditioning stress (17).

Paragraph 11 Gut: Prior exposure to ischemic preconditioning renders rats (62),
dogs (20) and pigs (40) resistant to ischemia/reperfusion-induced oxidative injury,
intestinal permeability, and systemic inflammatory responses. Protection against
endotoxin-induced mortality is also related to induction of HSP70 in gut tissues
(36). Preconditioning heat stress has been shown to prevent damage to intestinal
mucosa, neutrophil infiltration, and repress inflammatory cytokine cascades
following ischemia/reperfusion challenge (23, 88, 89). Preconditioning has been
further shown to maintain high rates of leukocyte rolling in the face of
ischemia/reperfusion stress, resulting in reduced leukocyte adherence to
postcapillary venules and reduced migration of leukocytes into interstitial spaces
of rat mesentery (8). The heat shock response also directly represses NK cell
mediated cytotoxicity via reductions in perforin mRNA and protein expression
(29). This reduction in perforin may serve to reduce epithelial and endothelial
barrier damage associated with excessive perforin release. Heat preconditioning
also has been shown to reverse sulfonic acid-induced colitis in rats, preventing the
rise in neutrophil chemoattractant factors, TNF-a, and myleoperoxidase activity
reported in sham treated animals (44).

Paragraph 12 Vasculature: Thermal preconditioning protects coronary arteries
against ischemia/reperfusion-induced cytokine injury, and the time course of
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HSP70 synthesis in myocardial tissues is inversely correlated with plasma Il-1b
levels (27). Reductions in LPS-induced vascular permeability and TNF-a content
of dermal tissues have also been reported in mice that were previously exposed to
preconditioning thermal stress (90). In this study, the inhibition of vascular
permeability correlated temporally with increased HSP70 content of dermal
tissues. Transgenic HSP70 over-expression has been reported to protect against
hyperthermia, circulatory shock, and cerebral ischemia in a mouse heatstroke
model (50). Thermal preconditioning increases HSP70 in lung tissue and reduces
LPS-induced myeloperoxidase activity and lung barrier permeability in rats (43).

Suppressing the heat shock response prevents acquisition of integrative
thermotolerance in laboratory animal experiments.
Paragraph 13 From the above sections, it is clear that the heat shock response is the
default pathway for multiple stress adaptations. Based on this observation, one can
understand why it is difficult to block the heat shock response in the integrated organism.
Attempts have been made to genetically alter mice to prevent stress-mediated HSP70
induction (37), but they have been largely unsuccessful. Further, because HSF-1,
independent of HSP70, is known to confer protection against various physiological
stressors, simply blocking HSP70 should not block the entire heat shock response. For
this reason, a common approach used by investigators is to pharmacologically stimulate
the heat shock response in an animal model, comparing this response to that of animals
receiving both a pharmacologic stimulator and a pharmacologic repressor. The following
paragraph details observed responses to pharmacologic-mediated HSP70 over34

expression. The next paragraph examines what happens when animals are simultaneously
dosed with a pharmacologic HSP70 stimulator and repressor.

Paragraph 14 Geranylgeranylacetone (GGA) is a potent stimulator of HSP70 synthesis
in respiratory, myocardial, hepatic, and renal tissues (30, 72, 95). It has been reported to
provide protection against oxidant-induced injury in intestinal cell culture experiments
(71) and NSAID-induced membrane permeability in a liposome model (98). These
effects are identical to observations in cultured monolayers after a preconditioning
thermal stress. Rodent models utilizing GGA to stimulate the heat shock response have
reported restoration of gastrointestinal mucosal barrier integrity and repression of
inflammatory cytokines in mice recovering from experimental atrophic gastritis (55).
GGA has also been reported to repress LPS-induced inflammatory cytokine (TNF-a and
Il-6) production and prevent LPS-induced mortality (68), similar to previous reports on
mice following a preconditioning thermal stress (22).

Paragraph 15 Adding the HSF-1/HSP70 inhibitor quercetin to these rodent models
increases atrophic gastritis-associated inflammation (55) and removes protection against
LPS-induced mortality (68). Quercetin also has been reported to suppress liver HSP70
synthesis and prevent liver regeneration in mice recovering from partial hepatectomy
(83). Quercetin also blocks sodium arsenite-induced HSP70 elevation in rat small
intestine, preventing the reductions in ischemia/reperfusion-induced plasma TNF-a,
neutrophil chemoattractant factor 1, and tissue injury that are normally associated with
this preconditioning stimulus (96).
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III. Laboratory Heat Acclimation
Paragraph 16 Repeated exposure to exercise, to heat stress, or to exercise-heat stress 1)
improves the capacity of animals and humans to dissipate heat (58, 79,); 2) reduces
animal mortality to experimental heatstroke (38); and 3) reduces incidence of exertional
heat illness in humans (7). This protection is long lasting and results from improvements
in sweating threshold and sensitivity, increased cutaneous blood flow, and increased
plasma volume (67). The combination of these factors reduces cardiovascular and
thermoregulatory strain (58). Heat acclimation also stimulates the heat shock response,
but its significance in the whole body responses to heat exposure remains unclear. In this
section we examine evidence that 1) heat acclimation stimulates the heat shock response;
and 2) suppression of the heat shock response prevents humans and animals from
acclimating to repeated heat exposure.

Laboratory heat acclimation activates the heat shock response and increases HSP70 in
animals and humans.
Paragraph 17 Laboratory heat acclimation has been shown to increase HSP72
expression in cardiac tissues of mice (60), and in peripheral blood mononuclear cells
(PBMC) (58, 63, 101) and serum (80 ,101) of humans. The practical implications of an
increase in serum HSP70 are unclear. Higher constitutive HSP70 levels in PBMCs may
contribute to reductions in inflammatory cytokine production (47), in a manner similar to
animals in nature. It has been reported that increased constitutive HSP70 content in
PBMCs (101) and myocardial tissues (33) after heat acclimation, result in reduced de
novo HSP70 synthesis in response to a subsequent thermal challenge (63). However, this
reduced HSP response to heat may have been due to a reduction in heat storage, as mice
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and humans in these studies were heat acclimated using a traditional, constant work level
heat acclimation protocol. Using a controlled hyperthermia method of heat acclimation,
which requires subjects to sustain a core temperature >39°C for 50 minutes on each of 7
days of successive heat exposure, we have shown a similar HSP70 accumulation in
PBMC on day 1 and day 7 of exercise/heat stress (47), despite an elevated baseline.
Mouse models suggest the increase in constitutive baseline HSP70 protein levels may be
retained for >1 month following heat acclimation (93). We have recently confirmed these
findings in human subjects (47).

Paragraph 18 It has been speculated that thermotolerance (ability to avoid exertional
heat illness) in heat acclimated human populations may result from heat shock-mediated
improvements in gastrointestinal barrier function (49). Observations of: 1)improved
epithelial barrier function in heat-preconditioned monolayer experiments (15, 16, 17, 65);
2) marathon runners with core temperatures >42°C exhibiting no outward symptoms of
endotoxemia (61); and 3) reduced circulating endotoxin concentrations in trained versus
untrained runners during exposure to identical exercise/heat stress (81) tend to support
this opinion. However, caution is advised when interpreting the results of these human
studies, as they relied on intact populations and did not measure heat acclimationmediated changes in gastrointestinal barrier permeability directly. We recently examined
gastrointestinal barrier responses to 7-days of heat acclimation exercise in humans, and
were unable to detect any improvements in epithelial barrier function (47). Additional
observations from this study are detailed in the following section.
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Suppressing the heat shock response prevents animals and humans from acclimating
to laboratory heat/exercise exposure.
Paragraph 19 A recent study examined the capacity of humans to acclimate to
exercise/heat exposure under the influence of the HSF-1/HSP70 inhibitor quercetin (47).
Subjects in this study were exposed to 7-days of heat acclimation exercise in normal
dietary conditions, and again while ingesting 2 g/d quercetin supplementation. The
condition order was counterbalanced, supplementation was double blind, and >3months
elapsed between trials (washout). As compared to their individual responses under
placebo supplementation, subjects acclimated while taking quercetin exhibited an
attenuated cellular heat shock response to exercise, greater gastrointestinal barrier
permeability, and increased concentrations of inflammatory cytokines in plasma. These
findings in the exercising human mirror those in quercetin-supplemented cells (35),
tissues (16, 17) and animals (55, 68) challenged with heat and LPS stressors. It was
further noted that subjects under quercetin supplementation, subjects did not acquire the
cardiovascular and thermoregulatory benefits traditionally associated with heat
acclimation. This was an unexpected finding, and may possibly be explained by cytokinemediated feedback to the central temperature controller (51).

Paragraph 20 Similar findings have been reported in a mouse model. Maloyan (2002)
examined the ability of rats to acclimatize to 30 days of passive heat exposure under
normal conditions, and also under the influence of beta-adrenergic blockade (blocks
HSP70) (59). Rats that were acclimatized under HSP70 blockade exhibited decreased
heat endurance when compared to their control counterparts (32). Further, while heat
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acclimatization conferred complete protection against ischemia-induced infarct in rats
acclimated under normal conditions, rats acclimated under HSP70 blockade were no
more protected than control rats, who had received no preconditioning exposure (34).

Paragraph 21 From these studies we conclude that animals and humans that have been
pharmacologically manipulated to suppress HSP70 induction receive little or no benefit
from exposure to preconditioning heat stress.

IV. Natural Heat Acclimatization
Paragraph 22 The previous sections provided clear evidence that HSF-1 and HSP-70,
both individually and together, are necessary for successful induction of integrated
thermotolerance and acclimation in laboratory experiments. In this section we extend
these observations to animals in nature. We focus on evidence that 1) the heat shock
response contributes to natural heat acclimatization; and 2) an absent or insufficient heat
shock response renders animals intolerant to natural thermal stress exposure.

The heat shock response contributes to natural heat acclimatization.
Paragraph 23 In nature, it has been established that thermotolerant organisms have
higher HSP70 mRNA and protein content in cells and tissues under non-stress conditions
and at normal physiological temperatures. In fact, this adaptation has been shown
conserved across species of mussels (6), crabs (87), snails (94), fish (10, 11), ants (25),
salamanders (70) and other lizards (97). The common link between these organisms is
environmental; they all reside in environments that are prone to rapid temperature
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changes. In light of this observation, higher constitutive HSP70 in these organisms has
been speculated to confer protection against sudden, acute thermal exposure, when the
rate of de novo HSP70 production would be too slow to offer protection. The desert ant
species Cataglyphis bombycina is an excellent example of this fact. High constitutive
levels of HSP70 allow Cataglyphis to forage at midday in the Saharra desert, tolerating
body temperatures in excess of 55°C (25). This adaptation is vital to Cataglyphis
survival, as it affords a slightly higher critical thermal maximum than Acanthodactylus
dumerili, a predatory lizard species that is similarly thermally adapted (99). Further
evidence of themotolerance contributing to selection bias in nature is provided by the
blue mussel species M. galloprovincialis, which has migrated from the Mediterranean
Sea to out-compete native mussel species (M. traossulus) along the California coastline.
This takeover, likely resulting from differences in the critical thermal maximum for
cardiac function of these two species (31°C and 26°C for M. galloprovincialis and M.
traossulus, respectively), has resulted in complete replacement of the native species along
the southern half of the California Coastline (5).

Paragraph 24 Parallel studies on human skin fibroblasts suggest similar adaptations
occur in geographically diverse human populations. Lyhsako (1994) compared HSP70
responses of skin fibroblasts of ethnic Turkmen living in the desserts of central Asia to
those of European Russians residing in temperate climates (57). While skin fibroblasts
from heat acclimatized Turks exhibited robust HSP70 responses through 6 hours of
exposure to 42.5°C heat stress, Russian fibroblasts exhibited similar responses through 4
hours of thermal exposure, but dropped to an almost undetectable level by the 6th hour of
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exposure. It should also be noted that Turkmen fibroblasts were remarkably resilient to
heat shock-induced mortality, while Russian fibroblasts were remarkably susceptible.

An insufficient or absent heat shock response prevents natural heat acclimatization.
Paragraph 25 The pacific oyster Crassostrea gigas is particularly susceptible to thermal
exposure in the period following the summer spawning season. Mass mortality, which
can exceed 50% of the total observed population , is related to insufficient accumulation
of HSP70 in gill tissues upon thermal stress exposure (53). There is also evidence of less
thermotolerant species of land (97) and sea (100) dwellers disappearing from their natural
habitats at temperatures that would require synthesis of HSP70. H. Attentuae is a hydra
species with unstable HSP70 mRNA, which prevents it from accumulating HSP70
protein in response to thermal exposure (26). Acclimatizing this hydra species to nonlethal temperatures does not induce thermotolerance, but instead further sensitizes it to
heat-induced mortality (3). It is interesting to note that the increased mortality reported in
this hydra species following “preconditioning” thermal stress is similar to the loss of
preconditioning benefits in laboratory animals under pharmacological HSP70 inhibition
(14; 68).

Insufficient activation of the heat shock response renders humans intolerant to heat
exposure in nature.
Paragraph 26 Recent research suggests that insufficient activation of the heat shock
system may also contribute to heat intolerance in active military populations. These
soldiers exhibit excessive metabolic heat storage and physiological strain in response to
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exertional heat stress, and are at increased risk of exertional heat illness over the general
population (18). When challenged with a standard heat tolerance tests (3.5mph, 40°C,
40% RH), heat intolerant individuals exhibited disruptions in the heat shock response at
both the transcript (HSF-1) and protein (HSP70) levels (64). These authors suggested that
the sluggish vasomotor responses exhibited by heat intolerant subjects may be a
reflection of insufficient HSP70 accumulation in the central nervous system. This
suggestion is supported by previous reports of HSP70-mediated potentiation of
sympathetic and parasympathetic responses elicited by the nucleus tractus solitarius,
which contributed to improved baroreceptor responsiveness and avoidance of heat strokemediated cerebral ischemia and hypotension (52). Further support is provided by
observations of reduced HSP70 production in the ventral paraventricular and lateral
magnocellular nuclei of aged animals exposed to thermal stress. It has been speculated
that the attenuated heat shock response reported in aged animals (28) and humans (86)
may contribute to their increased susceptibility to classic heatstroke (32). Continuing
research in this area will likely add considerably to our understanding of heatstrokerelated pathology.

Perspectives.
Paragraph 27 Based on recent studies, there is now sufficient data to support the interconnection between changes that occur in the cell (thermotolerance) and changes that
occur in the whole organism (heat acclimation). It is now clear that heat acclimation is
associated with improved tolerance of gut-associated bacteria; however, whether or not
heat acclimation confers direct benefits on gastrointestinal tissues remains to be seen.
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There is also direct evidence of both down regulated cytokine production and improved
cytokine tolerance in animals and humans responding to heat acclimation and other forms
of preconditioning exposure. Further, these is evidence that pharmacologic suppression of
the heat shock response, in addition to preventing acquisition of integrated
thermotolerance, also limits acquisition of the heat acclimated phenotype. Studies
examining the role of heat shock proteins in central nervous system adaptations to heat
acclimation represent an exciting new area of research; one that will likely greatly
advance our understanding of the integration between molecular biology and whole body
responses to heat exposure.

Figure 1: Thermotolerance and heat acclimation are related through the heat shock
response. We have coined the term “integrated thermotolerance” to describe this
relationship.
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CHAPTER III
RESEARCH MANUSCRIPT
This chapter presents a research manuscript, entitled “Thermotolerance and Heat
Acclimation share a common mechanism in humans”. This manuscript will be submitted
to the Proceedings of the National Academy of Sciences. It is authored by Matthew
Kuennen, Trevor Gillum, Karol Dokladny, Edward Bedrick, Sue Schneider, and Pope
Moseley. The manuscript follows the formatting and style guidelines of the journal. The
references cited are provided at the end of the manuscript.
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ABSTRACT.
Thermotolerance and heat acclimation are key adaptation processes that have been
hitherto viewed as separate physiologic phenomena. Here we show these processes share
a common basis, as both are governed by the heat shock response. We evaluated the
effects of a standard laboratory heat shock response-inhibitor (QUERCETIN; 2000mg/d)
on established markers of thermotolerance [gastrointestinal barrier permeability, plasma
TNF-a, Il-6, and Il-10 concentrations; leukocyte HSP70 content(HSP70)] and heat
acclimation [reduced body temperatures, heart rate, and physiologic strain in response to
exercise/heat stress] in male subjects (n=8) completing a 7-day heat acclimation protocol.
These same subjects completed an identical protocol under placebo supplementation
(PLACEBO). QUERCETIN increased gastrointestinal barrier permeability and TNF-a on
the 1st day of exercise/heat stress, no differences in these variables were reported in
PLACEBO. Exercise HSP70 responses were increased and plasma cytokines (Il-6 and Il10) were decreased on the 7th day of heat acclimation in PLACEBO; with concomitant
reductions in exercise body temperatures, heart rate, and physiologic strain. In contrast,
gastrointestinal barrier permeability remained elevated, HSP70 was not increased, Il-6
and Il-10 were not decreased, and exercise body temperatures were not reduced on the 7th
day of heat acclimation in QUERCETIN. While exercise heart rate and physiologic strain
were reduced in the QUERCETIN group, this occurred much later in exercise than with
PLACEBO. Consistent with the concept that thermotolerance and heat acclimation are
related through the heat shock response, repeated exercise/heat stress reduces circulating
cytokine concentrations and increases cytoprotective HSP70, contributing to reductions
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in both cellular and systemic markers of heat strain. Exercising under the influence of a
heat shock response-inhibitor prevents both cellular and systemic heat adaptations.

INTRODUCTION.
Paragraph 1. Prior exposure to a single preconditioning heat stress allows cells (1),
tissues (2), and animals (3) to survive an otherwise lethal heat shock. This protection,
termed thermotolerance, is synonymous with the heat shock response. While the major
function of the heat shock response is protein management (4), the heat shock response
has also been shown to enhance epithelial barrier resistance to heat exposure (5, 6, 7) and,
in animals, to reduce inflammatory cytokine production through inhibition of NFKB (8).
Together these improvements limit stress-mediated inflammation by preventing
endotoxin translocation into the portal circulation and limiting the systemic inflammatory
response.

Paragraph 2. Repeated exposure to exercise, to heat stress, or to exercise-heat stress
improves the capacity of animals and humans to dissipate heat (9, 10) and reduces
incidence of exertional heat illness (11, 12). This protection entails a set of major
physiological and metabolic adaptations and has been termed heat acclimation.
Acclimatization in nature and acclimation in laboratory settings is long lasting and results
from improvements in sweat sensitivity and rate, cutaneous vasodilaton, and increased
plasma volume (13). Heat acclimation also invokes the heat shock response (14), but the
role of the heat shock response in acclimatization is largely ignored, since the heat shock
response is considered to be an adaptation primarily conferring thermotolerance. We have
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proposed that the cellular mechanisms that convey acquired thermotolerance in animals
and humans might also contribute to the systemic adaptations associated with the heat
acclimated phenotype (15). The evidence across animal phyla, including ants (16),
lizards (17), hydra (18), and other ocean dwellers (19, 20) suggest contributions of the
heat shock response to natural heat acclimatization. Here we show through HSF-1
inhibition, that blunting the cellular heat shock response in exercising humans increases
both intestinal permeability and inflammatory cytokine response from exercise.
Surprisingly, HSF-1 inhibition rendered human subjects both heat intolerant and blocked
their exercise acclimation, uncovering a previously unappreciated link between
thermotolerance and the acclimatized phenotype in humans.

RESULTS.
Paragraph 3. Baseline Characteristics. Eight men [mean(SEM), age: 28(1.6) yr, body
mass: 77.0(3.5) kg, height: 178.4(2.5) cm, body fat: 5.9(0.7) %, maximal oxygen uptake
55.6(2.3) ml·kg-1·min-1] participated in this study. Participants were healthy, physically
active, and did not disclose history of heat illness or gastrointestinal barrier dysfunction.
Individual subjects completed 7 days of heat acclimation exercise in either QUERCETIN
or PLACEBO supplemented conditions, allowed 95(9) days for condition washout, then
repeated HA in the opposite condition. Condition order was counterbalanced and
supplementation was double-blind. Data were collected during winter and spring months
(October – March) to minimize effects of natural heat acclimatization.

Paragraph 4. Thermotolerance (1-day). The ability of the heat shock response to confer
benefits on gastrointestinal barrier function and inflammatory cytokine responses in
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cellular (5, 6, 7) and animal models (8, 21) is well established; however, these beneficial
adaptations have not yet been examined in a human exercise model. For this reason we
measured subjects’ gastrointestinal barrier and cytokine responses to an acute bout of
exercise/heat stress under normal physiologic conditions (PLACEBO) and also under the
influence of the HSF-1 inhibitor quercetin (QUERCETIN).

Paragraph 5. We used the synthetic disaccharide lactulose (242kDa) to assess exerciseinduced alterations in GI barrier function. We also assessed plasma endotoxin levels, to
determine if alterations in GI barrier function contributed to increased endotoxin transit
into circulation. Because TNF-a, Il-6, and Il-10 are known responders to endotoxin
exposure and correlate strongly with the end order dysfunctions that comprise human
exertional heat illness (22, 23), we measured these cytokines in plasma. In addition, we
measured heat shock protein 70 (HSP70) concentrations in peripheral blood mononuclear
cells (PBMCs) responding to exercise stress.

Paragraph 6. Under PLACEBO conditions, urinary lactulose excretion and plasma
endotoxin levels were not increased on day 1(p= 0.480 and 0.224; respectively),
suggesting that this acute bout of exercise/heat stress was insufficient stimulus to cause a
detectable increase in gastrointestinal permeability. In agreement with a prior publication
from our laboratory (14), we also did not detect an increase in subjects plasma TNF-a
concentrations with exercise (p= 0.269). Plasma Il-6 (p= 0.000) and Il-10 (p= 0.001)
concentrations showed the expected increases with exercise, with Il-6 being increased
immediately post exercise (p= 0.000), 2 hours post exercise (p= 0.000), and 4 hours post
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exercise (p=0.000); and Il-10 being increased immediately post exercise (p= 0.009) and 2
hours post exercise (p=0.008). We did not detect any increases in PBMC HSP70 content
with exercise (p= 0.327).

Paragraph 7. Exposure to the HSF-1 inhibitor (QUERCETIN) significantly altered the
exercise response compared to placebo exposed subjects. Quercetin exposure resulted in
an increase in both urinary lactulose excretion (p= 0.032) and plasma TNF-a
concentrations (p= 0.015) with exercise. Plasma endotoxin levels also tended (p=0.124)
to increase with exercise; this non-significant finding may be explained by a competent
reticuloendothelial system filtering endotoxin that had crossed the gastrointestinal barrier,
before it reached the systemic circulation. Il-6 (p= 0.000) and Il-10 (p= 0.001) exercise
responses were similar to that reported in PLACEBO, with Il-6 being increased
immediately post exercise (p= 0.000), 2 hours post exercise (p= 0.000), and 4 hours post
exercise (p=0.025); and Il-10 being increased immediately post exercise (p= 0.001). We
did not detect an increase in PBMC HSP70 content with exercise (p= 0.144). We
speculate that the increased TNF-a plasma concentration under QUERCETIN might
reflect increased production by liver macrophages responding to endotoxin spillover,
consistent with the inflammatory model of heat stress (15).

Paragraph 8. Acquired Thermotolerance (7-day). After the effects of HSF-1 inhibition
on human cellular, tissue, and plasma responses to an acute bout of exercise/heat stress
had been determined, we next sought to determine what effect repeated bouts of
exercise/heat stress would have on these responses. To examine these effects we had
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subjects perform 7 consecutive days of exercise/heat stress in the presence
(QUERCETIN) or absence (PLACEBO) of HSF-1 inhibition.

Paragraph 9. In PLACEBO, urinary lactulose excretion (p= 0.230), plasma endotoxin
(p=0.297) and plasma TNF-a concentrations (p= 0.085) were not affected by the repeated
exercise/heat stress. The plasma Il-6 (p= 0.000) response to exercise remained fairly
consistent, with plasma Il-6 concentrations again being increased immediately post (p=
0.000) and 2 hours post exercise (p= 0.026). However, unlike that reported for acute
exercise/heat exposure on day 1, Il-6 had returned to baseline by 4 hours post exercise
(p= 0.072). Also in contrast to our findings on day 1, we did not detect an increase in Il10 with exercise following repeated exercise/heat stress (p=0.069). In contrast to our
findings for PBMC HSP70 content on day 1 (NS), we detected an increase in HSP70 with
exercise following repeated exercise/heat stress (p= 0.049), at 4 hours post exercise
(p=0.011). This was an expected finding, and is in agreement with our laboratory’s
previous observations in subjects completing a 10-day heat acclimation protocol (14).

Paragraph 10. QUERCETIN supplementation resulted in persistent, exercise induced
increases in urinary lactulose excretion (p= 0.021), indicating that exercise conditioning
under HSF-1 inhibition could not overcome this defect. Plasma endotoxin levels also rose
with exercise (p=0.0316), suggesting that the impairment in gastrointestinal barrier
function resulting from multiple days of exercise/heat stress was severe enough to
exceed the endotoxin clearing capacity of the reticuloendothelial system. As such, these
data are quite consistent with our previous reports on the inhibitory effect of quercetin on
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epithelial barrier conditioning in vitro (5, 6, 7). They also support reports by other labs of
attenuated gastrointestinal barrier restitution in vivo (24). While gastrointestinal
permeability remained, we did not find a persistent increase in plasma TNF-a at rest or
with exercise (p= 0.569) in these subjects. Thus, there was a decline in post-exercise
TNF-a between days 1 and 7 of the exercise protocol. Similar to that reported for the
same subjects under PLACEBO supplementation, Il-6 (p= 0.000) remained affected by
exercise, with plasma concentrations being increased immediately post exercise (p=
0.000) and 2 hours post exercise (p=0.000). However, unlike that reported on day 7 for
PLACEBO supplementation, plasma Il-6 concentrations remained elevated 4 hours post
exercise (p=0.045). We also noted differences in plasma Il-10 responses to exercise/heat
stress on day 7 of PLACEBO and QUERCETIN supplementation; in the former there
was no increase with exercise (p=0.069), while in the latter the increase (p=0.043) with
exercise was retained (immediately post exercise; p=0.051). In further contrast to what
we reported for these subjects under PLACEBO supplementation, we did not detect an
increase in HSP70 with exercise (p= 0.188).

Paragraph 11. Insufficiencies in gastrointestinal barrier function following both acute
and chronic exposure to exercise/heat stress; in conjunction with increased endotoxin
appearance in circulation; concomitant increases in inflammatory cytokine production
(TNF-a); and diminished HSP70 production in leukocytes responding to chronic exercise,
heat, and endotoxin stresses suggest that thermotolerance was dramatically altered by
HSF-1 inhibition. It is also interesting to note that Il-6 and Il-10 exercise responses were
attenuated following exposure to chronic exercise/heat stress under PLACEBO, but not
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QUERCETIN supplementation. As Il-6 is an inflammatory cytokine associated with
gastrointestinal barrier disruption (25) and Il-10 is an anti-inflammatory cytokine
associated with improvements in gastrointestinal barrier function (26), and both are
known responders to endotoxin stimulation (23), these differences are likely artifact
resulting from sustained gastrointestinal barrier dysfunction. Il-10 is also a repressor of
TNF-a response; suggesting that maintenance of high Il-10 levels with chronic
exercise/heat stress might explain the reduction in TNF-a from day 1 to day 7 of
exercise/heat stress under QUERCETIN supplementation. Alternatively, as quercetin has
been previously shown to reduce NF-KB activity in macrophages responding to LPS
exposure (27), this may also reflect a direct action of dietary quercetin supplementation.
The increase in exercise HSP70 levels in PLACEBO, and lack thereof in QUERCETIN,
suggests that repeated dosing with the HSF-1 inhibitor quercetin may have contributed to
a diminished heat shock response. An attenuated heat shock response in the face of
increased stimulus for HSP70 induction (> circulating endotoxin and inflammatory
cytokines) is intriguing.
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Fig. 1. The HSF-1 inhibitor quercetin alters well established markers of thermotolerance in humans
responding to 7 days of repeated exercise/heat stress. (A) urinary lactulose excretion in non-exercise/heat
stress conditions (Rest) and on the 1st day of exercise/heat stress under placebo (left panel) and quercetin
(right panel) conditions. (B) urinary lactulose excretion in non-exercise/heat stress conditions (Rest) and on
the 7th day of exercise/heat stress under placebo (left panel) and quercetin (right panel) conditions. (C)
plasma endotoxin at rest (rest) and immediately following exercise on the first day of exercise/heat stress
under placebo (left panel) and quercetin (right panel) conditions. (D) plasma endotoxin at rest (rest) and
immediately following exercise on the seventh day of exercise/heat stress under placebo (left panel) and
quercetin (right panel) conditions. *Increased from pre-exercise value, p< 0.05. Data are mean ± SEM, n=8
for all panels.
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Fig. 2. The HSF-1 inhibitor quercetin alters well established markers of thermotolerance in humans
responding to an acute bout of exercise/heat stress. Data were collected on the first day of heat acclimation
exercise. (A) plasma TNF-a; (B) plasma Il-6; and (C) plasma Il-10 before exercise (Pre), after exercise
(Post), two hours after exercise (2-Post) and 4 hours after exercise (4-post) under placebo (top of panel) and
quercetin (bottom of panel) conditions.*Increased from pre-exercise value, p<.05. Data are mean ± SEM,
n=8 for all panels.

Fig. 3. The HSF-1 inhibitor quercetin alters well established markers of thermotolerance in humans
responding to 7 days of repeated exercise/heat stress. Data were collected on the 7th day of heat acclimation
exercise. (A) plasma TNF-a; (B) plasma Il-6; and (C) plasma Il-10 before exercise (Pre), after exercise
(Post), two hours after exercise (2-Post) and 4 hours after exercise (4-post) under placebo (top of panel) and
quercetin (bottom of panel) conditions. *Increased from pre-exercise value, p< 0.05. Data are mean ± SEM,
n=8 for all panels.
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Fig. 4. The HSF-1 inhibitor quercetin alters production of stress-inducible heat shock protein 70 (HSP70)
in response to exercise/heat stress. HSP70 protein content of peripheral blood mononuclear cells (PBMC)
responding to (A) acute and (B) chronic exercise/heat stress. Measurements were taken before exercise
(Pre), after exercise (Post), two hours after exercise (2-Post) and 4 hours after exercise (4-post) under
placebo (top of panel) and quercetin (bottom of panel) conditions. (C) HSP70 protein content of PBMC
was increased in response to chronic exercise/heat stress under placebo, but not quercetin supplemented
conditions. Data represents change score, derived from subtracting HSP70 response on day 1 from response
on day 7, at each individual time point. *Increased from pre-exercise value, p<.05. Data are mean ± SEM,
n=8 for all panels.

Paragraph 12. Acquisition of the Heat Acclimated Phenotype. Given the clear
differences in exercise associated gut permeability to lactulose, cytokine production, and
HSP70 in PBMC between QUERCETIN and PLACEBO exposed subjects, we next
examined the physiologic profiles of the 2 groups following a standardized heat
acclimation protocol. In essence, we sought to determine the effect of HSF-1 inhibition,
which altered markers of thermotolerance, on subjects’ ability to achieve the heat
acclimated phenotype. Heat acclimation is known to stimulate multiple systemic
adaptations, including reductions in the rate of rise of core, skin, and mean body
temperatures with exercise, exercise heart rate response, and physiological strain, as well
as increases in plasma volume and whole body sweat responses (13). We quantified these
same improvements in the present study by having subjects perform an exercise bout at
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the beginning and end of the 7 day heat acclimation protocol. Exercise workload (45 min
at 50% VO2max) and ambient environmental conditions (46.5°C, 20%RH) were matched
between bouts (additional data on conditional equality available in METHODS).

Paragraph 13. Each of core temperature (p= 0.022), mean skin temperature (p= 0.001),
and mean body temperature (p= 0.002) were reduced after 7 days of heat acclimation
under PLACEBO supplementation. Core temperature was reduced from 40 - 45; mean
skin temperature was reduced from 35 - 45; and mean body temperature was reduced
from 30 - 45 minutes of exercise, respectively. Heart rate (p= 0.010) and physiological
strain (p= 0.016) responses to exercise were also improved, with heart rate being reduced
from 5 - 45 minutes of exercise, and physiological strain being reduced from 10 - 45
minutes of exercise. We also noted significant increases in whole body sweat rate (from
31±1.6 ml/min to 34.3±2.2 ml/min; p= 0.044) and plasma volume expansion (16±4%).

Paragraph 14. Quercetin blocked the ability of subjects to heat acclimate through
exercise. Contrary to our findings for the same subjects under PLACEBO
supplementation, we did not detect any improvements in core temperature (p= 0.130),
mean skin temperature (p= 0.974), or mean body temperature (p= 0.109) responses to
exercise/heat stress with QUERCETIN. Further, while overall improvements in heart rate
(p= 0.020) and physiologic strain (p= 0.017) responses to exercise/heat stress were
detected in the QUERCETIN condition, reductions in these responses came much later in
exercise. As compared to the PLACEBO condition, where improvements in heart rate
and physiologic strain were evident at 5 and 10 minutes of exercise, respectively; under
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QUERCETIN improvements were not detected until 20 and 25 minutes of exercise had
elapsed. While thermoregulatory responses in subjects under QUERCETIN
supplementation were clearly compromised, these differences cannot be explained by
differences in subjects’ ability to sweat (which increased from 30.3±3.4 ml/min to
35.2±3.7 ml/min; p= 0.002) or to expand their plasma volume (plasma volume expansion
= 16±5%), which were identical (p= 0.486 and 0.535; respectively) between conditions.

Fig. 5. The HSF-1 inhibitor quercetin alters well established systemic adaptations that characterize the heat
acclimated phenotype. (A) Core temperature; (B) mean skin temperature; (C) mean body temperature; (D)
heart rate; and (E) physiological strain responses (scored 0-10, where 0 = no strain and 10 = high strain) to
a matched exercise bout performed at the start (dark squares) and end (light squares) of the 7-day heat
acclimation protocol under placebo (top of panel) and quercetin (bottom of panel) conditions. *Improved
exercise response, p < 0.05. Data are mean ± SEM, n=8 for all panels.

DISCUSSION.
Paragraph 15. In the present study we examined the effect of a standard laboratory HSF1 inhibitor, quercetin, on well described markers of thermotolerance and heat acclimation
in humans. We found that oral quercetin supplementation at 2 g/d was sufficient to
disrupt the normal cellular accumulation of HSP70 in PBMC. The blunted HSP70
response was associated with impairments in gastrointestinal barrier function and
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inflammatory/anti-inflammatory cytokine profiles. These findings in the exercising
human mirror those in cells (28), tissues (6, 7) and animals (24, 29). While this is the first
clear example of this effect in humans, the major finding of this study was the ability of
HSF-1 inhibition to impede acquisition of the acclimated phenotype. This study provides
the clearest support to date for the link between thermotolerance and heat acclimation.

Paragraph 16. HSF-1 inhibition reduces acquisition of heat acclimated phenotype.
The ability of HSF-1 inhibition to confer detriments on systemic adaptations to chronic
exercise/heat stress becomes more intriguing when one considers that all the changes in
physiology associated with heat acclimation are designed to limit the rise in body
temperature for a given amount of work in the heat. How then, could HSF-1 inhibition
confer this loss of acclamatory fitness? Referencing classic studies of both natural
acclimatization and laboratory heat acclimation, we note multiple instances where active
heat exposure is reported to increase animal (30) and human (31, 32) capacity to tolerate
higher internal temperatures before cessation of work. This is not part of the set of
adaptations we usually associate with either acclimatization or acclimation, and suggests
a more basic cellular mechanism.

Paragraph 17. The present study is the first to demonstrate a link between
thermotolerance and acclimation in humans through inhibition of the heat shock system.
However, the association between thermotolerance and adaptation has been suggested in
prior reports which took advantage of natural differences between species. Perhaps the
best example of such adaptations is the Saharan ant Cataglyphis bombycina, which shows
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elevated levels of HSP70 at low ambient temperatures (25°C). This adaptation has been
suggested to contribute to C. bombycina capacity to forage at midday, tolerating surface
temperatures 15°C higher than all other desert ant species (16). This adaptation is vital to
C. bombycina survival, as the associated increase in CTM (53-55°C) gives it a slight
competitive advantage over Acanthodactylus dumerili, a predatory lizard species with
similar thermal adaptation (33). There is also evidence of elevated HSP70 levels at
normal ambient temperatures in lizards (34) and multiple insect species (35, 36) that
reside in environments prone to rapid temperature change. This high constitutive HSP70
expression has been suggested to allow these organisms to perform work at elevated
temperatures, where de novo HSP70 synthesis would be too slow to confer benefit (15).
Benefits of this adaptation are apparent when one examines Hydra attenuate, a hydra
species that has naturally lost the ability to accumulate HSP70 in response to thermal
exposure. Acclimating this hydra species does not induce thermotolerance, rather, it
increases mortality to subsequent thermal exposure (18). In all of these studies, the
natural experiment suggested that improved heat tolerance, as measured by work in the
heat, was associated with an elevated HSP response. Likewise, an evolved decrease in
HSP response predicted less capability to perform work in heat and heat intolerance.

Paragraph 18. Intriguingly, a similar repression of the heat shock response has been
reported in heat intolerant military personnel, and has been suggested to explain the
excessive metabolic heat storage and physiological strain these soldiers experience in
response to exertional heat stress (37). It should also be noted that these soldiers are at
significantly increased risk of developing exertional heat illness than the general
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population (37, 38). Reduced acclimatory capacity has also been reported in rats
acclimatized under HSP70 blockade (39). Like that reported by heat intolerant military
personnel, and for otherwise healthy subjects in the present study, rats that were
acclimated under HSP70 blockade exhibited decreased heat endurance and increased
tissue damage in response to subsequent thermal challenge (40).

Paragraph 19. Conclusions. In this study we reported that supplementation with an
HSF-1 inhibitor prior to a single bout of exercise heat stress increased gastrointestinal
barrier permeability and inflammatory cytokine responses. Following 7 days of repeated
exercise/heat stress the increase in gastrointestinal barrier permeability and altered
exercise cytokine responses remained. More importantly, the ability of repeated
exercise/heat stress to confer the heat acclimated phenotype was diminished in these
subjects. These data provide evidence of considerable overlap in human thermotolerance
and heat acclimation responses, and for the first time link benefits of each through
activation of the heat shock response.

MATERIALS & METHODS.
Paragraph 20. The present study was approved by the ethics committee of the University
of New Mexico, Albuquerque, USA. All study participants gave written informed
consent prior to study participation. Experiments were conducted according to the
principles expressed in the Declaration of Helsinki.
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Paragraph 21. Experimental Design. Eight subjects completed 7 days of heat acclimation
(HA) exercise in both PLACEBO and QUERCETIN supplemented conditions. Each
subject began the study by providing baseline measures of fitness (maximal oxygen
consumption and body composition). They next completed a baseline test of
gastrointestinal barrier permeability, in non-exercise/heat stress conditions. On the
following day subjects performed a standardized heat tolerance test to provide baseline
measurements of their capacity to tolerate exercise heat stress. After a 7-day washout,
subjects began the heat acclimation protocol. Additional measures of gastrointestinal
barrier permeability, cytokines, and HSP70 were performed on the 1st and 7th days of heat
acclimation exercise, allowing researchers to examine subjects’ acute and acquired
thermotolerance responses. A second heat tolerance test was performed on the 6th day of
heat acclimation exercise, allowing researchers to examine subjects’ ability to acclimate
to repeated exercise/heat exposure. Figure 6 provides a schematic of the study design.
These measures are described in greater detail in the following sections.

Fig. 6. Study Schematic.
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Paragraph 22. Baseline Measures of Fitness. Each subject performed a continuous
graded treadmill test in a temperate room (22ºC to 24ºC, 30% to 40% RH) to determine
VO2pk through open circuit spirometry. VO2pk was defined as the highest 30-second
value when two of the following criteria were met: (a) a plateau (change in VO2 < 150
ml.min-1) with increase in workload, (b) a maximal respiratory exchange ratio greater
than 1.1, and (c) heart rate (HR) greater than 95% of the age-predicted maximum (220 −
age). Percent body fat was calculated from the average of 3 skinfold sites (41).

Paragraph 23. Gastrointestinal Barrier Permeability. Following an overnight fast
subjects ingested 10g lactulose (Kristalose, Cumberland Pharmaceuticals) dissolved in 50
ml dH2O. Subjects collected their urine into sterile containers for 8 hours post ingestion,
at which time 10 ml was aliquoted and stored at -80°C for subsequent analysis of urinary
lactulose excretion.

Paragraph 24. Standardized Heat Tolerance Tests. Subjects began each heat tolerance
test by providing a urine sample, from which hydration was assessed via urine
osmolality. They next inserted a calibrated rectal thermistor (YSI Precision 4400 Series,
Yellow Springs Inc) 12 cm into the rectum. Following insertion subjects provided a nude
body mass to 0.1 kg, then donned athletic shorts, socks, and shoes and entered the
environmental chamber. Subjects were next fitted with a telemetric heart rate (HR)
transmitter strap and watch (S810i series, Polar). Uncovered skin thermistors (Grant
Instruments Ltd) were then attached to the upper arm, upper thigh, chest, and calf with
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elastic straps. Heart rate, core, and skin temperatures were recorded at 5 minute intervals
during exercise.

Paragraph 25. Each subject completed 45 minutes of exercise at a workload
corresponding to 50% of his measured VO2max. Subjects drank ad libitum during
exercise. Following exercise termination subjects immediately left the environmental
chamber, toweled dry, then provided a post-exercise nude body mass for calculation of
sweat losses and urine sample for hydration assessment. Differences in whole body
responses to exercise in the heat (core temperature, mean skin temperature, mean body
temperature, heart rate, physiological strain, plasma volume, and whole body sweat rate)
were calculated as previously described (14, 42). Great care was taken to minimize the
potential influence of extraneous variables (ambient environment, exercise
characteristics, and subject hydration status) on experimental design (Table 1).

Ambient Environment

Exercise Response

Hydration Status

Dry Bulb
Temperature
(°C)

Relative
Humidity
(%)

Oxygen
Uptake
(ml/kg/min)

Exercise
Workload
(m/s)

H2O
Intake
(L)

HT1
HT2

47.0(.4)
46.8(.4)

19.7(1.3)
21.0(1.6)

28.2(1.0)
27.3(1.5)

2.11(.15)
2.11(.15)

HT1
HT2

46.2(.4)
46.0(.4)

22.3(1.3)
21.2(1.3)

28.4(1.3)
27.6(1.6)

2.11(.15)
2.11(.15)

Urine Osmolality (mOsm/kg)

1.0(.13)
0.88(.12)

Pre
Exercise
487(71)
440(68)

Post
Exercise
392(87)
482(89)

0.94(.11)
0.88(.23)

475(81)
511(86)

436(85)
560(77)

Table 1. Equality of Heat Tolerance Tests. There were no differences in the ambient environment,
subject exercise responses, or hydration status between the 1st (HT1) and 2nd (HT2) heat tolerance tests in
either PLACEBO supplemented (shaded) or QUERCETIN supplemented (unshaded) conditions. Data are
mean(SEM).

Paragraph 26. Heat Acclimation Protocol. Subjects exercised in the environmental
chamber to increase their core temperature to > 39°C in 50 minutes of exercise. They
then rested in the environmental chamber for 10 minutes, followed immediately by
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another 50 minute exercise bout. This method of controlled hyperthermia allowed
subjects to maintain core temperature above 39°C for the entire second 50 min exercise
bout, providing for a greater and more sustained increase in core temperature over
traditional protocols (10). Workload (speed/ %grade) was recorded every five minutes
and oxygen consumption was recorded every 15 minutes during exercise. Additional
measures of oxygen consumption were taken 5 minutes after each workload transition.
Exercise termination criteria included 1) completing the full 100 minutes of exercise, 2)
core temperature > 39.5 oC, 3) HR > 98% of HRmax, or 4) subject request. Preparatory
and exercise procedures were otherwise identical to those described previously for the
heat tolerance tests. Additional measures of gastrointestinal barrier permeability and
blood samples for thermotolerance variables were taken on days 1 and 7 of heat
acclimation. Equality of mean core temperature (2nd 50min exercise bout), peak core
temperature, and mean exercise workloads are depicted in Table 2. Blood sampling and
assay techniques are described in further detail in the following sections.

Mean Core
Temperature (°C)

Peak Core
Temperature (°C)

Mean Exercise
Workload (m/s)

Day 1
39.02 (0.04)
39.33 (0.12)
1.75 (0.06)
Day 7
39.02 (0.04)
39.35 (0.09)
1.80 (0.06)
Day 1
38.93 (0.04)
39.28 (0.14)
1.77 (0.07)
Day 7
39.12 (0.03)
39.42 (0.06)
1.85 (0.07)
Table 2. Equality of Heat Acclimation Days 1 and 7. Mean and peak core temperatures, as well as mean
exercise workloads are depicted for the 1st and 7th days of heat acclimation in PLACEBO supplemented
(shaded) and QUERCETIN supplemented conditions (unshaded) conditions. Data are mean(SEM).

Paragraph 27. Blood sampling procedure. Posture-controlled blood samples were
collected without stasis from each subject before (pre), after (post), 2 hours post (2post)
and 4 hours post (4post) exercise on the 1st and 7th days of HA exercise via venipuncture
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of an antecubital vein. These samples were used to assess cytokine and HSP70 responses
to exercise. Additional posture-controlled blood samples were taken on each heat
tolerance test, prior to exercise. These samples were used to assess heat acclimationinduced changes in hematocrit and hemoglobin, from which plasma volume expansion
was calculated with a standardized formula (43).

Paragraph 28. Endotoxin. Plasma endotoxin was assessed with a limulus amebocyte
lysate chromogenic endpoint assay from Cell Sciences (HIT302, Canton, MA, USA)
sensitive to 1.4 pg/ml. Samples were diluted 1:3 in endotoxin free water, then heated at
75°C for 10 min. Following heating samples and controls were run in duplicate and
assessed relative to manufacturer provided standards. Endotoxin concentration was taken
as the average of sample absorbance after the control background had been removed.

Paragraph 29. Inflammatory/anti-inflammatory cytokines. Serum TNF-a was
assessed with a solid phase chemiluminescent immunometric assay (Immulite 1000 TNFa, Siemens Medical Solutions Diagnostics) sensitive to 1.7 pg/ml. Serum IL-6 was
assessed with an ELISA (Quantikine HS, R&D Systems) sensitive to 0.039 pg/ml.
Plasma Il-10 was assessed with an EIA (Titerzyme EIA, Assay Designs) sensitive to 3.75
pg/ml. All cytokines and standards were measured in duplicate and performed according
to manufacturer instructions.

Paragraph 30. HSP70. PBMCs were isolated from whole blood and analyzed for HSP70
protein content as described previously (14), with these modifications. The membrane
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was cut longitudinally after blocking. Primary monoclonal (SPA-812, Assay Designs)
and secondary polyclonal (81-6120, Invitrogen) antibodies were applied to the upper half
of the membrane for HSP70 detection. The lower half of the membrane was treated with
primary monoclonal (A5441, Sigma) and secondary polyclonal (61-0120, Invitrogen)
antibodies for B-actin detection. HSP70 was quantified relative to B-actin to control for
differences in gel loading.

Paragraph 31. Urinary lactulose excretion. Lactulose was quantified with an EIA (KFRUGL, Megazyme), with some deviations from manufacturer’s instructions. The
supplied glucose/fructose (0.2 mg/ml) standard was serially diluted 1:2. 55 µl of blank,
standard, or urine were added to 96 well microtiter plates, followed by 55ul of TAE, 10ul
of B-galactosidase, 10µl imidizole buffer, and 10 µl β – NAD+/ATP solution. The plate
was mixed and allowed to incubate for 3 minutes at 37°C, then read at 340nm to measure
background absorbance. The plate was next incubated at 37°C for 2 hours to allow bgalactosidase conversion of lactulose into free glucose and fructose. After incubation
hexokinase + G-6-P dehydrogenase solution was diluted 1:5 in TAE buffer, and 10ul was
added to all occupied wells. The plate was then mixed and incubated at 37°C for 5
minutes. Absorbance (340nm) was measured to determine free glucose concentration.
PGI was then diluted 1:5 in .5XTAE buffer, and 10ul was added to the plate. The plate
was then mixed, incubated at 37°C (5min), and read (340nm) to determine free fructose
concentration. Urinary lactulose concentration was quantified as the difference between
the A2 and A3 readings after background (A1) had been removed.
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Paragraph 32. Statistical Analyses. All statistical analyses were performed with
STATISTICA, version 7.1 (StatSoft, Tulsa, OK, USA). Variables were tested for normal
distribution using the Kolmogorov-Smirnov test. Nonnormally distributed variables were
log transformed to approximate a normal distribution before applying a t-test or repeated
measures analysis. The repeated factors assumption of sphericity was tested with
Mauchly’s sphericity test. When necessary, a Greenhouse-Geisser correction was applied
to the F-ratio to correct for sphericity violations. All data represent mean (SEM) for n=8.
Statistical significance was set at p < 0.05.

Paragraph 33. Gastrointestinal Barrier Permeability: Alterations from basal
gastrointestinal barrier function (lactulose and endotoxin) due to exercise/heat stress on
day 1 and day 7 of HA were assessed via paired t-tests. The relationship between
lactulose and endotoxin readings was examined via linear regression.

Paragraph 34. Molecular Responses to HA Exercise: Exercise alterations in TNF-a, Il6, Il-10, and HSP70 were assessed via one-way RM ANOVA (time). Dunnet’s test was
used to assess significant differences from baseline.

Paragraph 35. Whole Body Responses to HA Exercise: Alterations in core
temperature, mean skin temperature, mean body temperature, heart rate, and physiologic
strain responses to exercise on day 1 and day 7 of HA were assessed via two-way RM
ANOVAs (day * time). Tukeys post hoc tests were used to assess significant main effects

77

and interactions, where appropriate. Differences in plasma volume and whole body sweat
rate from day 1 to day 7 of HA were examined via paired t-tests.
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CHAPTER IV
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
Summary
The review manuscript titled “Heat shock proteins and heat adaptation of the
whole organism: An update” reviewed current evidence supporting contributions of the
heat shock response to heat adaptation of the whole organism. In addition, the review
manuscript examined evidence of natural and artificial suppression of the heat shock
response contributing to heat maladaptations of the whole organism. A systematic
process was used to detail these contributions at the level of the isolated cell, confluent
monolayer, isolated tissue, integrated animal, and integrated human.
The research manuscript titled “Thermotolerance and heat acclimation are related
through the cellular stress response” provided evidence of pharmacological (quercetin)
repression of the heat shock response contributing to increased gastrointestinal barrier
permeability and inflammatory cytokine responses in human subjects during exertional
heat stress. While this was the first demonstration of these findings in a human model,
they were expected, and in agreement with prior work performed in cell culture, tissue,
and animal models. An unexpected and intriguing finding was the diminished capacity of
subjects under quercetin supplementation to acclimate to exercise/heat exposure. This
was evidenced by non-improvement in core, skin, and mean body temperature, as well as
reduced improvement in heart rate and physiological strain responses to a matched
exercise bout performed at the beginning and end of the heat acclimation protocol. It is
important to note that other adaptations typically associated with heat acclimation,
namely plasma volume expansion and an increased sweat rate, were not altered by
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quercetin supplementation. A reduced acclimation capacity in the face of normal
mechanisms for heat dissipation suggests this response may be centrally mediated, but
this statement is speculatory and beyond the scope of the current study. As it stands, this
study provides the clearest support to date for the link between thermotolerance and heat
acclimation.

Conclusions
The significant findings presented in the research manuscript were: a)Acute
exercise/heat stress caused increased gut permeability and plasma TNF-a concentrations
(post) in subjects under quercetin, but not placebo supplementation; b)Acute
exercise/heat stress caused increased Il-6(post;2post;4post) and Il-10(post;2post) plasma
concentrations, but did not alter the HSP70 content of peripheral blood mononuclear
cells. This response was identical in quercetin and placebo supplemented subjects; c)
Chronic exercise/heat stress caused increased gut permeability in subjects under
quercetin, but not placebo supplementation; d)The increase in Il-6 with exercise was
retained in placebo(post; 2post) and quercetin(post;2post;4post) supplemented subjects
following chronic exercise/heat stress exposure; e)The increase in TNF-a noted in
quercetin supplemented subjects following acute exercise/heat stress was not retained
following chronic exposure to exercise/heat stress. TNF-a was also not increased in
placebo supplemented subjects following chronic exercise/heat stress exposure; f) Il-10
remained increased by exercise(post) in quercetin, but not placebo supplemented subjects
following chronic exercise/heat stress exposure; g)HSP70 was increased with
exercise(4post) in subjects under placebo, but not quercetin supplementation, indicating
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the expected rise in HSP70 following heat acclimation was retained in placebo, but
absent under quercetin supplementation; h) Core, skin, and mean body temperature
responses to a heat tolerance test were improved in subjects under placebo, but not
quercetin supplementation; i) Heart rate and physiological strain responses to a heat
tolerance test were improved in subjects under both placebo and quercetin
supplementation. However, improvements were noted earlier in exercise under placebo
supplementation; j) plasma volume was expanded and sweat rate was improved by heat
acclimation. Quercetin supplementation did not influence these variables.
These were also significant findings that were not presented in the research
manuscript. These included: a) plasma cytokine concentrations (TNF-a, Il-6, and Il-10)
are reduced by heat acclimation. Because heat acclimation was accomplished by a
controlled hyperthermia technique, which maintained subject core temperature >39°C for
a minimum of 50 minutes on each day of exercise/heat stress, these results are not a
reflection of reduced exercise/heat stress that have been noted in traditional heat
acclimation models; b) using this controlled hyperthermia technique, we reported an
increase in PBMC HSP70 content with exercise on the 7th day of heat acclimation. This
contrasts previous work performed in our lab, where an increase in basal HSP70 on day 6
and day 10 of heat acclimation were reported to limit HSP70 increases with exercise.
This is likely due to the use of controlled hyperthermia in the present study, versus
traditional heat acclimation in our prior research.
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Recommendations
1. This study was originally designed to examine whether contraindications existed
for the current practice of large-dose dietary quercetin supplementation in military
soldiers and endurance athletes. The possibility that dietary quercetin
supplementation may suppress the heat shock response and confer negative
consequences on human gastrointestinal tissues during exercise heat stress was
based on a small number of cell culture studies, and one animal model of LPSinduced sepsis. There were also a small number of animal studies supporting
antioxidant supplementation as reducing stress-induction of heat shock protein-70
and conferring negative consequences, but these were far from conclusive. At the
time we knew the study would benefit from prior testing in an animal model, but
there were insufficient time and resources to accomplish this. Based on the results
of this study in a human population, it is suggested a similar study be performed
in an animal population, under more controlled conditions.

2. The mechanism by which a functional heat shock response suppresses
gastrointestinal barrier dysfunction is not well understood. Human models limit
capacity to examine heat stress-induced alterations in gut tissues. Such studies
should be performed in animals, and should examine the transcription factors
HSF-1 and NF-KB. It is also recommended that the effects of quercetin
supplementation be tested in this model.
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3. We began this study with some assumptions. We assumed we would note a robust
disruption of gastrointestinal barrier permeability with acute exercise/heat stress.
We further assumed this permeability would be reduced by acclimating subjects
to exercise heat exposure. Neither effect was shown in subjects under placebo
supplementation. Questions remain as to whether this result was due to
insufficient method development on our part, or whether gastrointestinal barrier
integrity is truly not improved with heat acclimation. Further research should be
performed to examine this question.

4. The outcome variables tested in this study were sufficient to answer basic
questions about quercetin-induced gastrointestinal barrier permeability. Now that
these questions have been answered, further research should examine the effect of
quercetin-mediated gastrointestinal barrier dysfunction on other cytokines (Il-8),
acute phase proteins (CRP), and coagulation factors (complement) of interest.
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APPENDIX A

Supplemental Figure 1: Plasma Endotoxin. Data are presented individually (left) and
together (right). *significant at p< 0.05.
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APPENDIX B

Supplemental Figure 2: Urinary Lactulose Excretion. Data are presented individually
(left) and together (right). *significant at p< 0.05.
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APPENDIX C

Supplemental Figure 3: Core Temperature. Final (45 minute) core temperature values
for individual subjects are depicted (left) as well as core temperature values for the entire
45 minute exercise bout (right). *significant at p< 0.05.
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APPENDIX D

Supplemental Figure 4. The regression of systemic endotoxin vs urinary lactulose was
highly significant (r2=0.634), supporting lactulose as a useful marker of gastrointestinal
barrier permeability.

Supplemental Figures 5 and 6 Care should be taken not to apply linear regression to
non-significant findings. Figure 5 (left) represents the regression of lactulose on
endotoxin for the combination of placebo and quercetin supplemented conditions. Note
that r2 has been reduced to 0.351. Figure 6 (right) represents the regression of lactulose
on endotoxin for placebo supplemented conditions, Note that barrier leak was not shown
with either of these variables in the placebo condition, r2= -0.075, and the relationship in
inverted.
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APPENDIX E

Supplemental Figure 7. Extracellular HSP70 was measured in plasma of subjects
responding to (A) acute and (B) chronic exercise/heat stress. Measurements were taken
before exercise (Pre), after exercise (Post), two hours after exercise (2-Post) and 4 hours
after exercise (4-post) under placebo (top of panel) and quercetin (bottom of panel)
conditions. (C) Data are mean ± SEM, n=8 for all panels. This figure is provided only to
depict data collected with this dissertation, not for interpretation purposes. The large
standard error associated with this measurement leaves considerable doubt as to the
validity of this assay.
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APPENDIX F

Supplemental Figure 8. Interleukin 1b was measured in plasma of subjects responding
to (A) acute and (B) chronic exercise/heat stress. Measurements were taken before
exercise (Pre), after exercise (Post), two hours after exercise (2-Post) and 4 hours after
exercise (4-post) Data are mean ± SEM, n=6 for both panels. 3 subjects exercised under
placebo supplementation, and 3 subjects exercised under quercetin supplementation. This
figure is provided only to depict data collected with this dissertation, not for
interpretation purposes. The large standard error associated with this measurement leaves
considerable doubt as to the validity of this assay.
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APPENDIX G

Supplemental Figure 7. Glutathione peroxidase activity of subjects responding to (A)
acute and (B) chronic exercise/heat stress. Measurements were taken before exercise
(Pre), after exercise (Post), two hours after exercise (2-Post) and 4 hours after exercise (4post) Data are mean ± SEM, n=4 for both panels. 2 subjects exercised under placebo
supplementation, and 2 subjects exercised under quercetin supplementation. This figure is
provided only to depict data collected with this dissertation, not for interpretation
purposes. The UNM General Clinical Research Center, which funded this assay as part of
an NIH-appropriated grant, has ceased to exist. These data may be made available to the
investigator at a later date.
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APPENDIX H
The University of New Mexico Health Sciences Center
Consent to Participate in Research
Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response
You are being asked to participate in a research study performed by Dr. Pope Moseley, Principal
Investigator, and his associates from the Department of Internal Medicine and the Department of Health
Exercise and Sports Sciences. This research is testing whether a nutritional supplement called quercetin
increases heat stress (reduced tolerance to heat) during exercise.
Quercetin is found in common foods like apples, onions, berries, and leafy green vegetables. In addition to
dietary sources of quercetin, it is also sold in health food stores as a popular over the counter supplement.
Athletes take it to reduce their exercise stress, but we think it may affect their tolerance to heat. What
we’re interested in is how supplementing the diet with quercetin effects heat shock protein (HSP) levels
during repeated exercise in the heat. HSP are proteins your body makes in response to stress. They play a
role in protecting cells and the intestine lining against heat stress.
You are being asked to participate in this study because you are healthy, between the ages of 18-39 years,
and do not have a previous history of heat related injury or other serious disease that may prevent you from
being able to exercise in the heat. As many as 11 people will take part in this study at the University of
New Mexico.
This form will explain the research study, and will also explain the possible risks as well as the possible
benefits to you. We encourage you to talk with your family and friends before you decide to take part in
this research study. If you have any immediate questions, please ask one of the study investigators.
What will happen if I decide to participate?
If you agree to participate, the following things will happen:
Screening process & paperwork (Approximately 3 hours over TWO DAYS)
Study Day 1 - You will be asked to sign this informed consent, and a Health Insurance Portability and
Accountability Act (HIPAA) form. You will complete a health history/physical activity questionnaire and a
Heat Shock Protein Questionnaire.
Study Day 2 - Your blood pressure, height and weight will be measured. We will also draw a blood sample
of 1 teaspoon of blood from an arm vein to measure your glucose and cholesterol. You should not have
eaten for at least 12 hours prior to the blood draw. After this sample is processed the results will be sent to
the investigators, who will provide you with a copy.
- To determine the percentage of fat in your body, three skinfolds will be measured, by lightly pinching your
skin over the chest, abdomen & thigh.
- To determine your physical fitness, you will perform a maximal exercise test on a treadmill. The test will
last between 8 and 12 minutes, depending on your current exercise level. During the test we will take
breath samples, which allow us to calculate the maximal amount of oxygen your body is using. To collect
your breath samples, you will breathe through a sterile, rubber mouthpiece and wear a noseclip. This may
cause you to experience some discomfort (dry mouth) and feel confined. You will need to have at least
average aerobic fitness to qualify for this study.
Exercise and Heat Testing (OVERVIEW)
- You will be asked to participate in TWO EXERCISE AND HEAT TESTING CONDITIONS, separated
by at least 1 month. During one condition you will be given quecetin supplements twice a day for 7 days
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(powder taken in a glass of TANG, a flavored children’s beverage) and during the other condition, you will
be given a placebo (like a sugar pill) that is taken the same way. These two exercise and heat testing
conditions will occur randomly, meaning you have a 50/50 chance of starting the study in either test.
Neither you nor the investigator will know which condition you are in. Each condition will include 8 bouts
of exercise in the heat (lasting between 30 to 100 minutes). On Study Days 3, 12, and 18 you will go the
General Clinical Research Center (GCRC) at UNM hospital (5th Floor), where you will stay in a private
room overnight.
In both study conditions the GCRC kitchen will provide you with all meals and snacks, which you will
substitute for what you eat normally. You will begin eating these meals/snacks three days before starting
each study condition, and will continue eating them until that condition is finished. To make sure you like
all the foods included in the meals we will have you fill out a sheet that identifies foods you like and don’t
like. We will take you to the UNM hospital and show you where to pick these meals up. The hospital
would like you to take enough meals for 2 days, which means you will need to have a good sized
refrigerator to keep them in. If you live in the dorms or do not have access to a large refrigerator let us
know, and we will make alternative arrangements. We are giving you these meals so we can make sure you
are not eating large amounts of quercetin. It is very important that you eat all of the meals that are provided
to you and nothing else during the experiment. These meals will be big, and probably contain more calories
than you are used to eating, so you should not be hungry.
If you forget and eat something that was not part of these meals, you need to let us know. To aid you in this
we will give you a diet log, which you will use to write down everything you eat and drink each day. If we
find that you are repeatedly eating things that are not part of the diet we may, at our discretion, remove you
from the study.
EXERCISE AND HEAT TESTING CONDITION 1 (~84 hrs)
Study Day 3 - You will report to the GCRC at 5:00pm. When you arrive you will receive a controlled diet
and spend the night. The next morning before breakfast you will be asked to drink a cup of sugar water. We
will draw a blood sample (~ 1 tablespoon), collect all of your urine, and you will be monitored for the next
8 hours. Once you have finished this 8 hour monitoring period you will be able to go home.
Study Day 4 - You will report back to the Exercise Physiology Lab in Johnson Center the next morning to
begin the daily exercise portion of the study in the heat. During this visit, you will eat breakfast, have
another blood sample (~ 1 tablespoon) drawn, and a urine sample taken.
You will next be asked to insert a small, flexible probe 4 inches into your rectum so we can measure your
body temperature during the exercise. You will then exercise for 30 minutes on a treadmill at a moderate to
high intensity. The room you are exercising in is hot (42-44ºC; 107 – 111 ºF, 30-45% relative humidity)
because we are trying to increase your body temperature. At the end of the exercise you will stand for 5
minutes so we can draw another 1 tablespoon of your blood. We will monitor you for 1 hour to make sure
you do not have a bad reaction to exercising in the heat before being allowed to go home. You will have a
break on Study Days 3 – 5 and will eat your own diet during this time. On Study Day 6 you will pick up
your meals at the GCRC kitchen to prepare for the next exercise testing.
Study Days 12-18 - You will be asked to come back to the Exercise Physiology Laboratory 7 more times
over the next 10 days to perform more exercise in the heat. Like before, we will sample your urine on all of
these days. Just like before, we’ll draw another tablespoon of your blood before and after exercise on these
days, except for on Study Days 13 and 15. On these days we’ll give your arms a break. This is also when
supplementation of quercetin or placebo begins. You will be given a sports bottle that contains one of these
supplements, mixed with TANG.
The only difference between the exercise on these days and that on Study Day 4 is you’ll be working at a
lower intensity, for a longer period of time. So, this exercise will be divided into (2) 50 minute bouts
separated by a 30 minute break. After you finish, we will then provide you with a supplement that you will
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take home. You will need to drink it right before your last meal of the day. Once we’re sure you
understand these instructions and you have no other questions, you can go home.
On Days 12 and 18, we will need additional intestinal measurements. So, the evening before these sessions
you will report to the GCRC at 5:00pm. You will be admitted, provided meals, and spend the night, waking
up the next morning and drinking the sugar water just like you did in the first visit. This is where things
will change a little. You will be provided with the supplement in addition to your breakfast. You will then
be transported to Johnson Center for the exercise session. At the end of exercise you will not go home.
Instead, you will go back to the GCRC for a few hours to finish our measurements. We’ll also take some
more blood (2 tablespoons). When you finish this day you will have successfully finished the 1st study
condition. Your next appointment, where you will begin the 2nd condition, will be in about 1 month.
EXERCISE AND HEAT TESTING CONDITION 2 (~84 hrs):
After that 1 month has passed you will repeat the entire experiment in the opposite condition. So, if you got
the quercetin supplement in the 1st condition, you will get the powdered food coloring in this one, and vice
versa. When you finish this condition we will give you a survey to see if you can guess which condition
you got the supplement, and which condition you got the powdered food coloring.
Measurements made during testing:
1. Heart rate using a telemetric heart watch monitor which consists of a transmitter belt worn around the
chest and a receiver watch worn on your wrist.
2. Bodyweight using a scale. You will measure your own nude body weight before and after each exercise
session in a private room. On study days 12 – 18 the exercise session is divided into 2 bouts. We will need
another nude bodyweight between these exercise bouts to make sure we give you the right amount of fluids
to drink. Like before you will measure your own nude bodyweight, but this time researchers will remain in
the hot room to assist you in case of emergency.
3. Skin temperature using 4 skin thermistors (small pieces of metal used to measure temperature) attached
to you by elastic straps and tape at the upper arm, chest, upper leg, and calf.
4. Core temperature using a rectal thermometer inserted about 4 inches beyond the external anal sphincter.
The thermometer is flexible and about half the width of a pencil. You will be instructed on how to insert the
thermometer, and a lubricant will be provided to increase comfort.
5. Urine samples (1 tablespoon) will be taken before and after the exercise challenge to check your
hydration. We will also collect all of your urine after you drink the sugar water during the GCRC stays.
6. Blood samples will be drawn from a vein in your arm with a needle and syringe on days where we only
need 2 samples (2 tablespoons). To avoid having to stick you with needles more then 2 times per day, a
catheter will be inserted into a vein in your arm on study days 12 and 18, because we need 4 samples (4
tablespoons) on those days. The total number of needle sticks you will receive over the course of each
Exercise and Heat testing condition will be 12.
Since you are repeating this study in both conditions, approximately 34 tablespoons (around 2 cups) of your
blood will be drawn over the 2.5 months you are participating in the study: 1 teaspoon for screening and 17
tablespoons (around 1 cup) during each of the Exercise and Heat Testing Conditions.
We know that this is a lot to review at one time. To help you understand what we will be doing in this
study, we have attached a study calendar to the end of this form. It lists all tests we will perform, and
which tests you can expect each day.
How long will I be in this study?
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Participation in this study will require you to be in our laboratory for approximately 177 hours over a
period of about 11 weeks. This time will include about 3 hours for the preliminary meetings and screening
and 87 hours in each of the (2) study conditions; 21 hours on each of the 3 days where you are admitted to
the hospital, and 4 hours per day on the other 6 days of exercise in the heat. Only ~27 of these hours will
actually be involved with exercise, the rest of this time you will be staying at the hospital, eating the
provided breakfast, performing pretest procedures, or resting. Remember, the (2) study conditions are
separated by a 1 month break. Please, only agree to participate in this study if you think you will be able to
commit to participating in both conditions.
What are the risks or side effects of being in this study?
Every reasonable precaution will be taken to minimize risks during this study. As in any testing situation,
there are risks involved.
During the maximal treadmill exercise test you may experience extreme or accelerated fatigue, fainting,
breathlessness, psychological stress (i.e., panic). There may be some discomfort and feeling of confinement
from the use of the mouthpiece and nose clip. In rare instances maximal exercise can cause musculoskeletal
soreness and injury, and very rarely heart attack or death. Because you are young and healthy, your risk of
these things during exercise testing is very low. Investigators will monitor you during exercise, and will
stop you if you show any signs of problem.
During the exercise in the heat you may experience the same risks listed for the maximal exercise test, and
in extremely rare instances, heat exhaustion, heat stroke, or death. The conditions (environmental heat,
exercise) involved in this study pose a small risk of heat illness. This is unlikely as you will be screened
prior to study participation, and investigators will monitor your body temperatures and heart rate while you
exercise. Heat illness usually does not occur at core temperatures below 41oC (about 106°F), and we will
stop you if you reach 39.5°C (103°F). There may also be a risk of reduced male fertility for up to a month
following prolonged heat exposure.
Minor pain and discomfort may occur when inserting a needle or catheter to obtain blood, and there is a
slight risk of bruising or infection at the site of sampling. Sterile equipment and standard procedures will be
used to minimize these risks. You may feel some local discomfort, including slight pressure when you first
insert the rectal thermistor we will use to measure your body temperature. This discomfort will diminish
over time. When using these thermistors in other studies, subjects typically reported no remaining
sensation 5 to 10 minutes after insertion.
We are testing the nutritional supplement, quercetin, because we think it may cause slight changes in gut
permeability. Exercise, elevations of body temperature, fasting, and other states can cause the intestinal
barrier to be leaky. Research by a number of scientists has focused on the potential impact of this leak to
allow products in the intestine to transfer into the bloodstream. Much of this work has been done in tissue
culture cells. And while exercise itself may cause this leak, we believe it is important to understand whether
supplements like quercetin can make this leak greater. We do not anticipate that this should be a problem
for you, as the procedures in this study should cause only minor increases in gut permeability. The sugar
water we will use to study these effects does not pose any additional risk to you.
There will be some invasion of privacy in this study. A loss of privacy may be associated with the nude
weight measurements and the rectal temperature probe. Some private medical information (from the
medical history questions) will be obtained. There will also be some inconvenience to you. During both
conditions you will be asked to restrict your level of exertion and to eat the diet we provide you.
As with any research, there may be unforeseeable risks. There may be risks associated with stress,
emotional distress, inconvenience and possible loss of privacy. Every effort will be made to minimize any
risk that may occur. Emergency equipment (defibrillator and crash cart) are available in the Exercise
Physiology Laboratory and emergency procedures are established to call for help (in UNM Hospital
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doctors are on site, and in the Exercise Physiology Laboratory a doctor is in an adjacent building about 2
minutes away – in the Student Health Center).
For more information about risks and side effects, contact the Principal Investigator, Dr. Pope Moseley,
M.D. at 272-6314, who will discuss your concerns. You can also contact the medical monitor for the
Exercise Physiology Laboratory, Dr. Akshay Sood, M.D, at 272-8700.
What are the benefits to being in this study?
There are no direct benefits to you for participation in this study.
Your participation in this study will help us to determine if supplementing with quercertin prevents people
from getting the full benefit of repeated exercise in the heat. This is an important question, because many
people use quercetin, or products like quercetin, in combination with exercise in hot conditions. If quercetin
is found to reduce this benefit, this would help us design future studies on antioxidants and heat stress. This
could also be useful to the military, as they might choose to avoid supplementing with quercetin and other
antioxidants when preparing soldiers for desert combat.
What other choices do I have if I do not want to be in this study?
The only alternative is not participating in this study.
How will my information be kept confidential?
We will take measures to protect your privacy and the security of all your personal information, but we
cannot guarantee confidentiality of all study data. You will be assigned a study number and all data
collected in this study will be designated by this code to provide some confidentiality for the data records
and computer files. Only the consent forms and medical history information will include your name. This
information will be stored in a locked file cabinet separate from the site where the study data are stored.
Only investigators in this study will have access to the study code to be able to link your data to your name.
This study code will be destroyed 1 year after the study is published. The remaining data will be shredded
5 years after the study is published.
Information contained in your study records may be used only by study staff. The University of New
Mexico Health Sciences Center Human Research Review Committee (HRRC) that oversees human subject
research, will be permitted to access your records. There may be times when we are required by law to
share your information. However, your name will not be used in any published reports about this study. A
copy of this consent form will be kept in your medical record, again separate from the data or the code key
that links the codes and names.
What are the costs of taking part in this study?
You will not be charged for any study procedures.
What will happen if I am injured or become sick because I took part in this study?
No commitment is made by the University of New Mexico Health Sciences Center (UNMHSC) to provide
free medical care or money for injuries to participants in this study. If you are injured or become sick as a
result of this study, UNMHSC will provide you with emergency treatment, at your cost. It is important for
you to tell your study doctor immediately if you have been injured or become sick because of taking part in
this study. If you have any questions about these issues, or believe that you have been treated carelessly in
the study, please contact the Human Research Review Committee (HRRC) at the University of New
Mexico Health Sciences Center, Albuquerque, New Mexico 87131, (505) 272-1129 for more information.
Will I be paid for taking part in this study?
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In return for your time and the inconvenience of participating in this study, you will be paid up to a
maximum of $600 after you have completed both study conditions. If you do not complete the study, you
will be paid $100 for each overnight stay at GCRC that you have already completed. You will be mailed a
check approximately (3) weeks after completing each study condition. Compensation over $600 will be
reported to the IRS.
How will I know if you learn something new that may change my mind about participating?
You will be informed of any significant new findings that become available during the course of the study,
such as changes in the risks or benefits resulting from participating in the research or new alternatives to
participation that might change your mind about participating.
Can I stop being in the study once I begin?
Your participation in this study is completely voluntary. You have the right to choose not to participate or
to withdraw your participation at any point in this study without affecting your future health care or other
services to which you are entitled. If you are a student, your participation in this study will not influence
your future grades or any other interactions with the faculty. If you choose to withdraw from this study
please contact Matthew Kuennen at 505-314-4400 as soon as possible.
Whom can I call with questions or complaints about this study?
If you have any questions, concerns or complaints at any time about the research study, Dr. Pope Moseley
or his associates will be glad to answer them at 505-277-5248, Monday – Friday 8am – 5 pm. If you need
to contact someone after business hours or on weekends, please call Matt Kuennen, the study coordinator’s
cell phone at 505-314-4400. If you would like to speak with someone other than the research team, you
may call the UNMHSC HRRC at (505) 272-1129.
Whom can I call with questions about my rights as a research subject?
If you have questions regarding your rights as a research subject, you may call the UNMHSC HRRC at
(505) 272-1129. The HRRC is a group of people from UNM and the community who provide independent
oversight of safety and ethical issues related to research involving human subjects. For more information,
you may also access the HRRC website at http://hsc.unm.edu/som/research/hrrc/.
Consent
You are making a decision whether to participate in this study. Your signature below indicates that you
read the information provided (or the information was read to you). By signing this consent form, you are
not waiving any of your legal rights as a research subject.
__________________________________________________________________________________
I have had an opportunity to ask questions and all questions have been answered to my satisfaction. By
signing this consent form, I agree to participate in this study. A copy of this consent form will be provided
to you.
_____________________________
__________________________/_______
Name of subject (type or print)
Signature of Subject
Date
I have explained the research to the subject and answered all of his/her questions. I believe that he/she
understands the information in this consent form and freely consents to participate.
______________________________
Name of Investigator/
Research Team Member

_________________________/ __________
Signature of Investigator/
Date
Research Team Member
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APPENDIX I
UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER
HIPAA1 AUTHORIZATION TO USE AND DISCLOSE
PROTECTED HEALTH INFORMATION FOR RESEARCH PURPOSES
Title of Study: Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body
Stress Response
Principal Investigator:
Dr. Pope Moseley, Ph.D.
UNMHSC Department: Department of Internal Medicine
Mailing Address:
MSC 10 5550
Co-Investigators:
Dr. Burke Gurney, Dr. Cliff Qualls, Dr. Karol Dokladny, Dr.
Suzanne Schneider, Kevin Christmas, Matthew Kuennen, Trevor
Gillum, Michelle Kulovitz
Sponsor: GCRC
What is the purpose of this form? You have been asked to take part in a research study. The consent
form for this study describes your participation, and that information still applies. This extra form is
required by the federal Health Insurance Portability and Accountability Act (HIPAA). The purpose of this
form is to get your permission (authorization) to use health information about you that is created by or used
in connection with this research.
1.

What if I don’t want my personal health information (PHI) to be used in this research study?
You do not have to give this permission. Your decision not to sign this form will not change your
ability to get health care outside of this research study. However, if you do not sign, then you will not
be allowed to participate in the study.

2.

What PHI am I allowing to be used for this research? We will be using the results of your
cholesterol screening and self reported medical history to determine if you qualify for this study. If
you qualify, we will also take blood samples to examine heat shock protein and cytokine expression at
rest and in response to exercise in the heat. Information gathered from these samples will not be
included in your permanent health record.

3.

Where will researchers go to find my PHI? The records we will need to see for this study will
include the blood results sent to us from your screening blood sample and the medical history
questionnaire you filled out at the beginning of this study. We will not need to access any of your
medical records from your doctor or from the HRRC records.

4.

Who will be allowed to use my information for this research and why? The researchers named
above and their staff will be allowed to see and use your health information for this research study. It
may be used to check on your progress during the study, or analyze it along with information from
other study participants. Sometimes research information is shared with collaborators or other
institutions. Your records may also be reviewed by representatives of the research sponsor or funding
agency, the Food and Drug Administration (FDA) to check for quality, safety or effectiveness, or the
Human Research Review Committee (HRRC) for the purposes of oversight and subject safety and
compliance with human research regulations.

5.

Will my information be used in any other way? Your information used under this permission may
be subject to re-disclosure outside of the research study and be no longer protected under certain
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HIPAA is the Health Insurance Portability and Accountability Act of 1996, a federal law related to
privacy of health information.
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circumstances such as required reporting of abuse or neglect, required reporting for law enforcement
purposes, and for health oversight activities and public health purposes.
6.

What if I change my mind after I give this permission? You can change your mind and withdraw
this permission at any time by sending a written notice to the Principal Investigator at the mailing
address listed at the top of this form to inform the researcher of your decision. If you withdraw this
permission, the researcher may only use and share your information that has already been collected for
this study. No additional health information about you will be collected by or given to the researcher
for the purposes of this study.

7.

What are the privacy protections for my PHI used in this research study? HIPAA regulations
apply to personal health information in the records of health care providers and other groups that share
such information. There are some differences in how these regulations apply to research, as opposed
to regular health care. One difference is that you may not be able to look at your own records that
relate to this research study. These records may include your medical record, which you may not be
able to look at until the study is over. The HIPAA privacy protections may no longer apply once your
PHI has been shared with others who may be involved in this research.

8.

How long does this permission allow my PHI to be used? If you decide to be in this research study,
your permission to access and use your health information in this study may not expire, unless you
revoke or cancel it. Otherwise, we will use your information as long as it is needed for the duration of
the study.

I am the research participant or the personal representative authorized to act on behalf of the participant.
By signing this form, I am giving permission for my personal health information to be used in research as
described above. I will be given a copy of this authorization form after I have signed it.

_________________________________
Name of Research Subject

__________________________________ ____________
Signature of Subject/Legal Representative Date

___________________________________________________
Describe authority of legal representative
_________________________________ ___________________________________ _____________
Name of Person Obtaining Authorization Signature
Date
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APPENDIX K
Physician Order Sheet
HRRC/CTSC 08-606: Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole
Body Stress Response
PI and Physician: Pope Moseley, M.D. Phone: 272-6314, Lab Phone: 272-5882
Study Coordinator: Matt Kuennen. Phone: 314-4400, Lab Phone: 277-2658
Subject Name: __________________________________
Admit to 5E: Private Room

Date: _______________

Attending: Pope Moseley, MD

Estimated length of stay: 14 hours
Diagnoses: HRRC 08-606: Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole
Body Stress Response.
Condition: Study involves young, healthy patients who will perform daily exercise in a hot room to
acclimate to desert heat. Testing if nutritional supplement quercetin has any effect on heat acclimation.
Vital Signs: Day 1 on Admit: BP, Pulse, Temp, Weight
Activities: Day 1: check in, vital signs, supper, pm snack *Provide patient 4 large brown urine collection
containers for mannitol/lactulose urine sugar test on day 2
Day 2: discharge
Diet: CRC Metabolic Kitchen has orders for low quercetin meals. Ensure subjects eat all food, drink all
fluids provided.
Diet Restrictions: No caffeine after 2100 day 1
Begin overnight fast 2300 day 1
No food between 0700 and 1500 day 2 (water ad-lib)
No caffeine until 1500 day 2
Meds: Pt may bring prescription meds from home and self administer
Labs: Investigator provides patient mannitol/lactulose sugars dispensed in distilled water at 0700 day 2.
Immediately after consumption begin 8 hour urine collection. Aliquots given to Core Lab, who has orders
for processing.
Discharge Date: ____________________

Discharge Time:___0700__________

If any problems, concerns, or questions please notify Matt Kuennen: 314-4400; 277-2658.
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APPENDIX L
Flowsheet for Protocol #08-606 “Effect of Combined Exercise, Heat, and Quercetin Supplementation
on Whole Body Stress Response”
Principle Investigator: Pope Moseley, MD (Phone 272-6314)
Co-Investigators: Dr. Burke Gurney, Dr. Cliff Qualls, Dr. Karol Dokladny, Dr. Suzanne Schneider,
Kevin Christmas, Matthew Kuennen, Trevor Gillum
For study questions please contact Matt Kuennen, study coordinator:
work: 277-2658; 277-1419
cell: 314-4400
email:mkuennen@unm.edu
Admission: coordinated by Matt Kuennen
Patient Study Number______________ Date __________ Admission # ______________
Time

Study
Date

Party
Responsible

Procedures

Please initial
when complete

1700

1___
2 ___

not applicable
Inpatient

1720

2

Inpatient

NONE
Admit patient to Private Room 5E
Vital signs on admission
BP _________/_________
Pulse_________
Temp_________
Weight_______
Provide patient supper
MUST EAT/DRINK ALL PROVIDED

2000

2

Inpatient

2100
2300
0645

2
2
3__

Inpatient
Inpatient
Inpatient

0650

3

Inpatient

0700

3

Inpatient

0700

3

Inpatient

0715

3

Inpatient

Provide patent evening snack
MUST EAT/DRINK ALL PROVIDED
NO CAFFEINE AFTER 2100
PATIENT BEGIN OVERNIGHT FAST
Pick up 5g MANNITOL/ 10g LACTULOSE
aliquots and mixing cup from 5E medicine
storage:
Mix mannitol and lactulose
per instructions provided by Pharmacy
Provide patient w/ man/lac beverage:
MUST DRINK ENTIRE SOLUTION
-All urine produced by patient must be
collected for 8 hours (0700 – 1500hrs)
-Urine collected into 2 hr aliquots (e.g. 0-2
hrs; >2-4 hrs; >4-6 hrs; >6-8 hrs)
-Provide patient with sterile urine collection
container for 0-2 hr urine collection
-22 ml blood draw from antecubital vein
-Use 18 gauge needle, draw slowly
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
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8 hr fast

15 min post
man/lac

-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
Reconstitute 50g Our Family Orange
Breakfast Drink powder with 16.9 oz bottled
H2O
-Provide beverage to patient
-MUST DRINK ENTIRE BEVERAGE
-Provide patient with new urine container for
>2-4 hr urine collection
-Walk 0-2 hr urine container to Core lab
immediately
-Record urine volume in 0-2 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Provide patient with new urine container for
>4-6 hr urine collection
-Walk >2-4 hr urine container to Core lab
immediately

0715

3

Core Lab

0750

3

BioNutrition

0800

3

BioNutrition

0900

3

Inpatient

0900

3

Core Lab

1100

3

Inpatient

1100

3

Core Lab

1300

3

Inpatient

1300

3

Core Lab

1500

3

Inpatient

-D/C urine collection
-Walk >6-8 hr urine container to Core lab
immediately

1500

3

Core Lab

1500

3

BioNutrition

-Record urine volume in >6-8 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Provide patient with late lunch
-Provide patient with supper, evening snack,
and 2 bottled H2O (given as pack meals)

-Record urine volume in >2-4 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Provide patient with new urine container for
>6-8 hr urine collection
-Walk >4-6 hr urine container to Core lab
immediately
-Record urine volume in >4-6 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
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1 hr post man/lac

1530
0750

3
4___

Inpatient
BioNutrition

D/C patient to home
Reconstitute 50g Our Family Orange
Breakfast Drink powder with 16.9 oz bottled
H2O
-Have patient eat standardized breakfast/ drink
beverage in Outpatient office
-MUST EAT/DRINK ALL PROVIDED
-Pick up 2 each of: 10 ml EDTA vacutainer, 8
ml SST vacutainer, 5 ml sodium heparin
vacutainer, 4 ml EDTA vacutainer
-Walk patient to Johnson Center for exercise
-22 ml blood draw from antecubital vein
-Use 18 gauge needle, draw slowly
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-22 ml blood draw from antecubital vein
-Use 18 gauge needle, draw slowly
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
Deliver blood samples to Core lab
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
NONE

0800

4

BioNutrition

0830

4

Investigator

0900

4

Investigator

0930

4

Investigator

0945
0945

4
4

Investigator
Core Lab

5___

not applicable

0800

6___
7___
8___
9___

not applicable
not applicable
not applicable
BioNutrition

NONE
NONE
NONE
-Have patient eat standardized breakfast in
Outpatient office
-Instruct patient to eat/drink all provided
-Weigh-back any leftovers

0830

9

BioNutrition

0800

10__

BioNutrition

-Provide patient with morning snack, lunch,
afternoon snack, supper, evening snack, and 5
bottled H2O (given as pack meals)
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back
-Have patient eat standardized breakfast in
Outpatient office
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0830

10

BioNutrition

0800

11__

BioNutrition

0830

11

BioNutrition

1700

11

Inpatient

1720

11

Inpatient

2000

11

Inpatient

2100
2300
0645

11
11
12__

Inpatient
Inpatient
Inpatient

0650

12

Inpatient

0700

12

Inpatient

0700

12

Inpatient

-Instruct patient to eat/drink all provided
-Weigh-back any leftovers
-Provide patient with morning snack, lunch,
afternoon snack, supper, evening snack, and 5
bottled H2O (given as pack meals)
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back
-Have patient eat standardized breakfast in
Outpatient office
-Instruct patient to eat/drink all provided
-Weigh-back any leftovers
-Provide patient with morning snack, lunch,
afternoon snack, and 3 bottled H2O (given as
pack meals)
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover that
evening for Weigh-back
Admit patient to Private Room 5E
Vital signs on admission
BP _________/_________
Pulse_________
Temp_________
Weight_______
Provide patient supper
MUST EAT/DRINK ALL PROVIDED
Provide patent evening snack
MUST EAT/DRINK ALL PROVIDED
NO CAFFEINE AFTER 2100
PATIENT BEGINS OVERNIGHT FAST
Pick up 5g MANNITOL/ 10g LACTULOSE
aliquots and mixing cup from 5E medicine
storage:
Mix mannitol and lactulose
per instructions provided by Pharmacy
Provide patient w/ man/lac beverage:
MUST DRINK ENTIRE SOLUTION
-All urine produced by patient must be
collected for 8 hours (0700 – 1500hrs)
-Urine collected into 2 hr aliquots (e.g. 0-2
hrs; >2-4 hrs; >4-6 hrs; >6-8 hrs)
-Provide patient with sterile urine collection
container for 0-2 hr urine collection
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8 hr fast

0715

12

Inpatient

-Set patient with 18 gauge venous catheter in
LEFT antecubital fossa
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-Make catheter suitable for transport to
Johnson Center
-Make 0-2hr urine container suitable for
transport to Johnson Center
-Provide patient with an extra urine container
Provide INVESTIGATOR with 1g quercetin
or placebo aliquot, 50g Our Family Orange
Breakfast Drink powder aliquot, a 16.9 oz
bottled H2O, and a sports bottle

0715

12

Core Lab

0720

12

Inpatient

0725

12

BioNutrition

0730

12

Investigator

0745

12

Investigator

0755

12

Investigator

0800

12

Investigator

0800

12

Investigator

0850

12

Investigator

Have patient discontinue exercise: 1st bout is
complete

0855

12

Investigator

0900

12

Investigator

0910

12

Core Lab

Begin rehydrating patient with dH2O equal to
weight loss
-Provide patient with new urine container for
>2-4 hr urine collection
-Walk 0-2 hr urine container from Johnson
Center to Core Lab
-Record urine volume in 0-2 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine

0920

12

Investigator

15 min post
man/lac

TEMPORARY D/C patient to Johnson Center
Exercise Physiology Lab
Prepare patient for exercise
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
-Provide supplement beverage to patient
-MUST DRINK ENTIRE BEVERAGE
Have patient begin exercise challenge

Rehydration complete: Have patient perform
2nd exercise bout
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1 hr post man/lac

1010

12

Investigator

Have patient discontinue exercise: 2nd exercise
bout complete
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately

1025

12

Core Lab

1045

12

Investigator

1050

12

Investigator

-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-Make catheter and >2-4 hr urine container
suitable for transport to CTSC
Return patient to CTSC

1100

12

Investigator

1100

12

Core Lab

1210

12

Inpatient

1210

12

Core Lab

1300

12

Inpatient

1300

12

Core Lab

-Provide patient with new urine container for
>4-6 hr urine collection
-Walk >2-4 hr urine container to Core Lab
immediately
-Record urine volume in >2-4 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-Provide patient with new urine container for
>6-8 hr urine collection
-Walk >4-6 hr urine container to Core Lab
immediately
-Record urine volume in >4-6 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
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3 hr 10 min post
man/lac

5 hr 10 min post
man/lac
2 hr post
exercise

1410

12

Inpatient

-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-D/C urine collection
-Walk >6-8 hr urine container to Core lab
immediately
-Record urine volume in >6-8 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Provide patient with late lunch
-Provide patient with supper, evening snack,
and 2 bottled H2O (given as pack meals)
-Provide patient with SECOND DOSE of
quercetin/placebo (1g), 50g Our Family
Orange Breakfast Drink, a 16.9oz bottled
water, and a sports bottle
-Ensure patient understands how to mix
supplement/drink powder/water properly
-Instruct patient to take supplement with
supper
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back

1410

12

Core Lab

1500

12

Inpatient

1500

12

Core Lab

1500
1520

12
12

BioNutrition
BioNutrition

1530
0750

12
13 __

Inpatient
BioNutrition

D/C patient to home
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O

0800

13

BioNutrition

-Have patient eat standardized breakfast/ drink
supplement beverage in Outpatient office
-MUST EAT/DRINK ALL PROVIDED

0825

13

BioNutrition

-Provide patient with morning snack, lunch,
afternoon snack, supper, evening snack, and 5
bottled H2O (given as pack meals)
-Provide patient with SECOND DOSE of
quercetin/placebo (1g), 50g Our Family
Orange Breakfast Drink, a 16.9oz bottled
water, and a sports bottle
-Instruct patient to take supplement with
supper
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7 hr 10 min post
4 hr post
exercise

8 hr post man/lac

0750

14__

BioNutrition

0800

14

BioNutrition

0825

14

BioNutrition

0750

15__

BioNutrition

0800

15

BioNutrition

0825

15

BioNutrition

0750

16__

BioNutrition

0800

16

BioNutrition

0825

16

BioNutrition

-Ensure patient understands how to mix
supplement/drink powder/water properly
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
-Have patient eat standardized breakfast/ drink
supplement beverage in Outpatient office
-MUST EAT/DRINK ALL PROVIDED
-Provide patient with morning snack, lunch,
afternoon snack, supper, evening snack, and 5
bottled H2O (given as pack meals)
-Provide patient with SECOND DOSE of
quercetin/placebo (1g), 50g Our Family
Orange Breakfast Drink, a 16.9oz bottled
water, and a sports bottle
-Instruct patient to take supplement with
supper
-Ensure patient understands how to mix
supplement/drink powder/water properly
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
-Have patient eat standardized breakfast/ drink
supplement beverage in Outpatient office
-MUST EAT/DRINK ALL PROVIDED
-Provide patient with morning snack, lunch,
afternoon snack, supper, evening snack, and 5
bottled H2O (given as pack meals)
-Provide patient with SECOND DOSE of
quercetin/placebo (1g), 50g Our Family
Orange Breakfast Drink, a 16.9oz bottled
water, and a sports bottle
-Instruct patient to take supplement with
supper
-Ensure patient understands how to mix
supplement/drink powder/water properly
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
-Have patient eat standardized breakfast/ drink
supplement beverage in Outpatient office
-MUST EAT/DRINK ALL PROVIDED
-Provide patient with morning snack, lunch,
afternoon snack, supper, evening snack, and 5
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bottled H2O (given as pack meals)
-Provide patient with SECOND DOSE of
quercetin/placebo (1g), 50g Our Family
Orange Breakfast Drink, a 16.9oz bottled
water, and a sports bottle
-Instruct patient to take supplement with
supper
-Ensure patient understands how to mix
supplement/drink powder/water properly
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover
following am for Weigh-back
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
-Have patient eat standardized breakfast/ drink
supplement beverage in Outpatient office
-MUST EAT/DRINK ALL PROVIDED

0750

17__

BioNutrition

0800

17

BioNutrition

0810

17

Investigator

-Pick up 2 each of: 10 ml EDTA vacutainer, 8
ml SST vacutainer, 5 ml sodium heparin
vacutainer, 4 ml EDTA vacutainer

0820

17

BioNutrition

0900

17

Investigator

0930

17

Investigator

0945

17

Investigator

-Provide patient with morning snack, lunch,
afternoon snack, and 3 bottled H2O (given as
pack meals)
-Instruct patient to eat/drink all provided
-Instruct patient to bring back any leftover that
evening for Weigh-back
-Draw 22 ml blood from antecub
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Draw 22 ml blood from antecub
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
Deliver blood samples to Core lab

0945

17

Core Lab

1700

17

Inpatient

-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
Admit patient to Private Room 5E
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1710

17

Inpatient

Vital signs on admission
BP _________/_________
Pulse_________
Temp_________
Weight_______
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
Have patient eat standardized supper/ drink
supplement beverage
MUST EAT/DRINK ALL PROVIDED
Provide patient with evening snack
MUST EAT/DRINK ALL PROVIDED

1720

17

BioNutrition?

1725

17

BioNutrition?

2000

17

Inpatient

2100

17

Inpatient

NO CAFFEINE AFTER 2100

2300
0645

17
18__

Inpatient
Inpatient

0650

18

Inpatient

PATIENT BEGINS OVERNIGHT FAST
Pick up 5g MANNITOL/ 10g LACTULOSE
aliquots and mixing cup from 5E medicine
storage:
Mix mannitol and lactulose
per instructions provided by Pharmacy

0700

18

Inpatient

Provide patient w/ man/lac beverage:
MUST DRINK ENTIRE SOLUTION

0700

18

Inpatient

0715

18

Inpatient

0715

18

Core Lab

0720

18

Inpatient

-All urine produced by patient must be
collected for 8 hours (0700 – 1500hrs)
-Urine collected into 2 hr aliquots (e.g. 0-2
hrs; >2-4 hrs; >4-6 hrs; >6-8 hrs)
-Provide patient with sterile urine collection
container for 0-2 hr urine collection
-Set patient with 18 gauge venous catheter in
LEFT antecubital fossa
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-Make catheter suitable for transport to
Johnson Center
-Make 0-2hr urine container suitable for
transport to Johnson Center
-Provide patient with an extra urine container
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0725

18

BioNutrition

Provide INVESTIGATOR with 1g quercetin
or placebo aliquot, 50g Our Family Orange
Breakfast Drink powder aliquot, a 16.9 oz
bottled H2O, and a sports bottle
TEMPORARY D/C patient to Johnson Center
Exercise Physiology Lab
Prepare patient for exercise
Mix 1g quercetin or placebo with 50g Our
Family Orange Breakfast Drink powder and
reconstitute with 16.9 oz bottled H2O
-Provide supplement beverage to patient
-MUST DRINK ENTIRE BEVERAGE

0730

18

Investigator

0745
0755

18
18

Investigator
Investigator

0800

18

Investigator

0800
0850

18
18

Investigator
Investigator

Have patient begin exercise challenge
Have patient d/c exercise: 1st bout is complete

0855

18

Investigator

0900

18

Investigator

0910

18

Core Lab

0920

18

Investigator

1010

18

Investigator

1015

18

Investigator

1025

18

Core Lab

1045

18

Investigator

1050

18

Investigator

Begin rehydrating patient with dH2O equal to
weight loss
-Provide patient with new urine container for
>2-4 hr urine collection
-Walk 0-2 hr urine container from Johnson
Center to Core Lab
-Record urine volume in 0-2 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
Rehydration complete: Have patient perform
2nd exercise bout
Have patient discontinue exercise: 2nd exercise
bout complete
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
Walk blood samples from Johnson Center to
Core Lab
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-Make catheter and >2-4 hr urine container
suitable for transport to CTSC
Return patient to CTSC

1100

18

Investigator

1100

18

Core Lab

-Provide patient with new urine container for
>4-6 hr urine collection
-Walk >2-4 hr urine container to Core Lab
immediately
-Record urine volume in >2-4 hr urine
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1210

18

Inpatient

1210

18

Core Lab

1300

18

Inpatient

1300

18

Core Lab

1410

18

Inpatient

1410

18

Core Lab

1500

18

Inpatient

1500

18

Core Lab

1500

18

BioNutrition

container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-Provide patient with new urine container for
>6-8 hr urine collection
-Walk >4-6 hr urine container to Core Lab
immediately
-Record urine volume in >4-6 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Draw 22 ml blood
-Dispense 10 ml blood into 10 ml EDTA
vacutainer [purple top]
-Dispense 7 ml blood into 8 ml SST
vacutainer [red top]
-Dispense 4 ml blood into 5 ml sodium
heparin vacutainer [green top]
-Dispense 1 ml blood into 4 ml EDTA
vacutainer [purple top]
-Walk blood samples to Core lab immediately
-Separate blood according to provided “Blood
Collection Protocol”
-Assay blood for TNF-a, Il-6, and glutathione
peroxidase
-D/C urine collection
-Walk >6-8 hr urine container to Core lab
immediately
-Record urine volume in >6-8 hr urine
container
-Aliquot 6 ml sample into sterile container
-Store urine aliquot at -20°C
-Discard remaining urine
-Provide patient with CELEBRATION MEAL

1530

18

Inpatient

D/C patient to home

*After minimum of 3 month washout patient repeats entire study
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APPENDIX M
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APPENDIX N

Placebo Condition
Days 9-11
Days 12-18

Intake (Kcal/d)
3628.4 ± 47.5
3756.1 ± 61.4

Quercetin Condition Intake (Kcal/d)
Days 9-11
3636.1 ± 51.1
Days 12-18
3713.3 ± 50.3

CHO (g/d)
447.6 ± 7.3
476.0 ± 11.0

FAT (g/d)
133.8 ± 2.1
136.6 ± 2.3

PRO (g/d)
176.9 ± 3.2
172.9 ± 2.6

Q (g/d)
6.9 ± 0.3
8.0 ± 0.2

CHO (g/d)
446.0 ± 8.7
465.2 ± 8.2

FAT (g/d)
135.0 ± 1.9
136.4 ± 2.2

PRO (g/d)
177.3 ± 3.3
174.4 ± 2.7

Q (g/d)
6.8 ± 0.3
8.0 ± 0.2

Dietary Intake for Placebo and Quercetin Supplemented Conditions
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APPENDIX O
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APPENDIX P
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APPENDIX Q
08-606 Mixing Instructions: Placebo/Quercetin Supplement
Items Needed:
Brown glass bottle w/ 1g placebo/quercetin powder
50 g Our Family Orange Breakfast drink mix
16.9 oz bottled water
Mixing bottle (clear plastic, large opening)
Waxed paper square

Item Abbreviated Name:
Brown bottle
Orange mix
Bottled water
Clear bottle
Waxed paper

1.

Fold waxed paper lengthwise to create a crease. Unfold waxed paper and place on counter.

2.

Remove cap from clear bottle. Place clear bottle on top of waxed paper.

3.

Remove cap from brown bottle. Turn brown bottle upside down over clear bottle. (mouth of clear
bottle is big enough that brown bottle should fit inside).

4.

Carefully tap bottom of brown bottle to transfer placebo/quercetin powder to clear bottle. Put cap
back on brown bottle and place on waxed paper.

5.

Fill clear bottle to 8oz line with bottled water. Put cap back on clear bottle. Shake well, for at least
1 minute. Shake longer if you still see floating powder chunks.

6.

There is still some powder left in brown bottle. Take cap off brown bottle. Fill brown bottle ½
full with bottled water. Put cap back on brown bottle. Mix brown bottle well, for about 1 minute.

7.

Transfer fluid from brown bottle to clear bottle

8.

Repeat steps 6 and 7 until all powder has been removed from brown bottle.

9.

Add the rest of the bottled water to the clear bottle.

10. Add the orange mix to the clear bottle.
11. Cap the clear bottle. Mix clear bottle well, for about 1 minute. Mix longer if you still see floating
powder chunks.
12. Serve the drink.
*Drink to be served at room temperature. Please do not refrigerate drug bag.
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APPENDIX R
Core Lab: Blood Collection Protocol
From the 8 ml SST tube (contains 7 ml):
1. Il-1b –MOSELEY [500 ul]
2. TNF-a –CORE LAB [750 ul]
3. Il-6 –CORE LAB [750 ul]
From the 5 ml Na Heparin plasma tube (contains 4 ml):
1. Quercetin – MOSELEY [1.5 ml]
From the 4 ml EDTA plasma tube (contains 1 ml):
1. Glutathione peroxidase –CORE LAB
*you can spin these as needed to get samples of interest. The 10 ml EDTA plasma tube discussed
below cannot be spun. It will be processed with histopaque 1077 b/c we need to isolate PBMCs.

From the 10 ml EDTA plasma tube (contains 10 ml):
1. Il-10 – MOSELEY [1 ml]
2. Endotoxin – MOSELEY [1 ml]
3. Extracellular HSP72 – MOSELEY [1 ml]
PBMCs isolated from 10 ml EDTA plasma sample:
1. HSP72 – MOSELEY [aliquot ½ cell pellet into 1.7ml mini-eppendorf]
2. HSF-1 – MOSELEY [aliquot ½ cell pellet into 1.7ml mini-eppendorf]
*see page 2 for PBMC isolation procedure

Standard Label Template
Please label each sample with:
1. Date sample collected
2. What sample is (PBMC or PLASMA)
3. What sample collected for (e.g. HSP72, Il-1b, etc)
4. Subject number
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APPENDIX T
Data Sheet for Screening
Subject Code:________________________ Date______/______/______

Time: _________ am/pm

PB (mmHg)__________Temp (ºC) ________________ Humidity (%) ______________

Age_________

220-Age_________

Gender____

Height (in)_______

Height (cm)________

Weight (kg) ________ BMI (kg/m2) __________

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦
SKINFOLDS (mm)
1
2
3
AVG
CHEST
______
______
______
______
Db ______
ABDOMEN
______ ______
______
______ %BF ______
THIGH
______
______
______
______
♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦
Treadmill PROTOCOL
Time

Workload

VO2
(m/kg/min)

HR (BPM)

Time at termination:
Reason for termination:
VO2max (ml/kg/min):_________
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Blood Pressure
(mmHg)

RPE/symptoms

APPENDIX U
Subject Number_________
Condition (circle one)
Pre BW: ________
Post BW: ________

Date__________

HT1

IP2

HA2

HA3 HA4

HA5

HT2

IP3

H2O drank during test _____________

Bout 1
Time
0
5
10
15
20
25
30
35

HR

Db

WBGT

GT

WB

Tcore

Tarm

Tthigh

Tcalf

Tchest

Work

VO2

HR

Db

WBGT

GT

WB

Tcore

Tarm

Tthigh

Tcalf

Tchest

Work

VO2

40
45
50

Bout 2
Time
0
5
10
15
20
25
30
35
40
45
50

Hydration Status
Time
Pre
Post

Urine

Hematocrit
/
/
/
/
/
/

Notes:
Supplies ready for bloods?
_________
Radio?
_________
Squirrel logging at start of test?
_________
Disarm Squirrel before unplugging? _________
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Hemoglobin
/
/
/
/
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APPENDIX X
HRRC/CTSC 08-606: Study Budget
Item Description (manufacturer, product #, where produced):

Cost:

Funded by:

Lactulose (Quintron, QT02500-10-5, Milwaukee, WI, USA)

$187

GCRC 09

Mannitol (Spectrum, MA165-500GM, Gardena, CA, USA)

$146

GCRC 09

TNF-α assay (CTSC core lab, std procedure)

$2080

GCRC 09

Il-6 assay (CTSC core lab, std procedure)

$4160

GCRC 09

Glutathione peroxidase assay (CTSC core lab, std procedure)

$1456

GCRC 09

-

GCRC 09

Participant Reimbursement

$4800

GCRC 09

Cell Separation (Sigma Aldrich, Histopaque 1077, St. Louis, MO, USA)

$900

GCRC 09

Placebo (powdered food coloring purchased at Royal Icing)

$240

GCRC 09

UNM Pharmacy Dispensing Fees

$1764

GCRC 09

B-glucuronidase/arylsulfatase kit (Roche Diagnostics, 10127698001, Indianapolis, IN, USA)

$440

Gatorade 09

SPE cartridges from Waters (WAT094225, Milford, MA)

$555

Gatorade 09

Mannitol kit (Megazyme International, KFRUGL, Bray, County Wicklow, Ireland)

$950
$2500
$495

RPT 09
GRD 2010
SRAC 09

Nuclear Extraction Kit (Active Motif, 40010, Carlsbad, CA, USA)

$560

P Moseley

B-Actin 1° antibody (Sigma Aldrich, A3853, St. Louis, MO, USA)

$300

P Moseley

HSF-1 1°antibody (Assay Designs, SPA-950F, Ann Arbor, MI, USA)

$340

P Moseley

Participant Meals

High performance liquid chromatography (UNM Mass Spec charges $100/hr user fee)

$200

2° antibody (Assay Designs, SAB-300J, Ann Arbor, MI, USA)

P Moseley

Vacutainer tubes (BD, 366450, Franklin Lakes, NJ USA)

$170

S Schneider

Our Family drink mix (Nash Finch, Northfield, IL, USA)

$240

donation

Quercetin (Nutravail Technologies, QU995, Chantilly, VA, USA)

$1000

donation

eHSP ELISA kit (Assay Designs, EKS-715, Ann Arbor, MI, USA)

$1725

Endotoxin kit (Cell Sciences, HIT302, Canton, MA, USA)

$1800

Il-1b EIA kit. (Assay Designs, 900-029, Ann Arbor, MI, USA)

$1700

Il-10 EIA kit (Assay Designs, 900-036, Ann Arbor, MI, USA)

$2490

Mannitol Dehydrogenase (Megazyme International, MDH, Bray County, Wicklow, Ireland)

$300

GRD 08/09
Gatorade 09
GRD 08/09
Gatorade 09
GRD 08/09
Gatorade 09
GRD 08/09
Gatorade 09
H. Lin

B-glucuronidase/arylsulfatase kit (Roche Diagnostics,
10127698001, Indianapolis, IN, USA)

$440

SPE cartridges (Waters, WAT094225, Milford, MA, USA)

$555

Pipettors and tips (VWR Interantional, various #, Chicago, Il, USA)

$1000

$33493

Total Funding Required:
141

GRD 09/10
GRD 09/10
RPT 10
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